

# CATALOG 2 • 2005



## BECOME A MEMBER

Clinical and Laboratory Standards Institute recognizes that member organizations provide significant support to the organization and the voluntary consensus process. We offer your organization a wide range of membership options. Membership categories have been redefined and streamlined to provide your organization with documents in electronic and printed formats.

In addition to Basic membership, there are six other membership categories. For instance, Associate Active membership is for an institution that wants a broader, more active role in our consensus process; Healthcare Delivery Systems is designed to meet the needs of hospital/healthcare systems with networked laboratories; Corresponding Customized Membership is tailored for small institutions or departments performing specialized, discipline-specific, or a limited number or variety of medical tests.

For detailed information on all membership categories, see page 38; to join, see page 39. We encourage you to take full advantage of the reduced prices offered through membership.

- A** = Approved standard or guideline
- P** = Proposed standard or guideline
- R** = Report

## TABLE OF CONTENTS

Specialty Collections .....	3	Projects in Development .....	19
Standards and Guidelines .....	6	Videotapes .....	21
Healthcare Services .....	6	Infobase 2005 .....	21
Automation and Informatics .....	6	Toolkits .....	22
Clinical Chemistry and Toxicology .....	8	Library .....	25
Evaluation Protocols .....	9	Electronic Products and Reports .....	26
General Laboratory Practices .....	10	Product Price Listing .....	28
Hematology .....	11	Subject Index of Documents, Products, and Projects .....	31
Immunology and Ligand Assay .....	12	How to Order .....	36
Microbiology .....	13	Order Form .....	37
Molecular Methods .....	15	Membership Information .....	38
Point-of-Care Testing .....	16		
Electronic Archived Documents .....	17		
ISO Documents .....	18		
ISO/TC 212 Standards .....	18		

## PLUS NEW DOCUMENTS

<b>Glucose Monitoring in Settings Without Laboratory Support</b> AST4-A2 (May 2005).....	8
<b>Preparation and Testing of Reagent Water in the Clinical Laboratory</b> C3-P4 (June 2005).....	8
<b>User Verification of Performance for Precision and Trueness</b> EP15-A2 (June 2005).....	9
<b>Performance of the Bleeding Time Test</b> H45-A2 (June 2005) .....	12
<b>Procedures for Validation of INR and Local Calibration of PT/INR Systems</b> H54-A (August 2005).....	12
<b>Body Fluid Analysis for Cellular Composition</b> H56-P (August 2005) .....	12
<b>Quality Control MIC Limits for <i>Mycobacterium peregrinum</i> and <i>Staphylococcus aureus</i> (When Testing Rapidly Growing Mycobacteria); Informational Supplement</b> M24-S1 (August 2005).....	14
<b>Procedures for the Recovery and Identification of Parasites From the Intestinal Tract</b> M28-A2 (June 2005).....	14
<b>Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated From Aquatic Animals</b> M42-P (August 2005).....	15
<b>Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Proposed Guideline</b> M45-P (October 2005).....	15
<b>Methods for Broth Dilution Susceptibility Testing of Bacteria Isolated From Aquatic Animals</b> M49-P (August 2005) .....	15
<b>Diagnostic Nucleic Acid Microarrays</b> MM12-P (July 2005) .....	16
<b>Proficiency Testing (External Quality Assessment) for Molecular Methods</b> MM14-A (August 2005).....	16
<b>Use of External RNA Controls in Gene Expression Assays</b> MM16-P (July 2005).....	16

## PLUS

<b>Infobase 2005</b> .....	21
<b>Training and Competence Assessment Toolkit</b> (GP21-A2-C) (Available October 2005).....	23
<b>Library on CD-ROM</b> .....	25
<b>M100 CD-ROM</b> (M2-A8/M7-A6/M100-S15).....	26
<b>Proceedings From the QC for the Future Workshop</b> (X6-R).....	27

# Specialty Collections

## Save money – Purchase documents in a convenient, bound collection.

The volumes of Specialty Collections combine related standards and guidelines in key subject areas. The purchase price reflects a significant savings over the combined list price of the individual documents for both member and nonmember organizations.

Please refer to the collections below for a listing of the individual document titles, individual purchase prices, and the locations in the catalog for descriptions.

### Evaluation Protocols (SC1-L)

This volume provides help in choosing the right instruments and analytical methods for desired procedures, which is critical to the efficient operation of clinical laboratories. Included are procedures for evaluating precision, linearity, stated performance characteristics, and guidelines on clinical sensitivity and specificity. This collection contains:

- EP5-A2** – Precision (page 9)  
Members \$85 Nonmembers \$200
- EP6-A** – Linearity (page 9)  
Members \$60 Nonmembers \$120
- EP7-A** – Interference (page 9)  
Members \$85 Nonmembers \$200
- EP9-A2** – Comparison of Methods (page 9)  
Members \$60 Nonmembers \$120
- EP10-A2** – Preliminary Evaluation (page 9)  
Members \$60 Nonmembers \$120
- EP12-A** – Qualitative Test Performance (page 9)  
Members \$60 Nonmembers \$120
- EP14-A2** – Evaluation of Matrix Effects (page 9)  
Members \$60 Nonmembers \$120
- EP15-A2** – Verification of Performance (page 9)  
Members \$60 Nonmembers \$120
- EP17-A** – Limits of Detection and Limits of Quantitation (page 9)  
Members \$60 Nonmembers \$120
- GP10-A** – Assessment of Tests (page 10)  
Members \$50 Nonmembers \$100

**Members \$340 Nonmembers \$645**

### Specimen Collection (SC2-L)

SC2-L can be used to establish collection criteria for laboratory procedure manuals, patient care units, and phlebotomy team training manuals. This convenient reference includes standards with procedures for collection of venous, arterial, and capillary blood specimens, as well as single and timed urine specimens. The collection includes:

- GP16-A2** – Routine Urinalysis (page 10)  
Members \$60 Nonmembers \$120
- H3-A5** – Venipuncture (page 11)  
Members \$85 Nonmembers \$200
- H4-A5** – Capillary (page 11)  
Members \$60 Nonmembers \$120
- H11-A4** – Arterial Collection (page 9)  
Members \$60 Nonmembers \$120
- H21-A4** – Coagulation Specimens (page 11)  
Members \$85 Nonmembers \$200
- M15-A** – Parasitic Diseases (page 13)  
Members \$60 Nonmembers \$120
- M28-A2** – Fecal Parasitology (page 14)  
Members \$60 Nonmembers \$120
- M29-A3** – Protection of Laboratory Workers (page 14)  
Members \$100 Nonmembers \$200

**Members \$280 Nonmembers \$570**

### General Hematology (SC7-L)

This collection provides guidance for the laboratorian performing routine hematology procedures. Manual methodologies for determining the erythrocyte sedimentation rate and packed cell volume are included. The collection also provides recommendations for specimen processing; immunophenotyping lymphocytes and counting reticulocytes by flow cytometry; and a reference method for automated differential counting. It contains:

- H2-A4** – Erythrocyte Sedimentation Rate (ESR) (page 11)  
Members \$50 Nonmembers \$100
- H7-A3** – Microhematocrit (page 11)  
Members \$60 Nonmembers \$120
- H18-A3** – Handling and Processing (page 11)  
Members \$60 Nonmembers \$120
- H20-A** – Differential Count (page 11)  
Members \$50 Nonmembers \$100
- H42-A** – Flow Cytometry (page 12)  
Members \$50 Nonmembers \$100
- H44-A2** – Reticulocyte Counting (page 12)  
Members \$50 Nonmembers \$100
- H45-A2** – Bleeding Time Test (page 12)  
Members \$50 Nonmembers \$100

**Members \$190 Nonmembers \$400**

### Laboratory Safety (SC10-L)

This is a must-have collection for all clinical laboratory settings. The guidelines included provide practical recommendations for establishing protocols to ensure a safe work environment for employees. Because of its wide application, we recommend that this specialty collection be purchased as a complement to any or all of the other collections. It includes:

- GP5-A2** – Laboratory Waste (page 10)  
Members \$60 Nonmembers \$120
- GP17-A2** – Laboratory Safety (page 10)  
Members \$60 Nonmembers \$120
- M29-A3** – Protection of Laboratory Workers (page 14)  
Members \$100 Nonmembers \$200
- X3-R** – Needlestick (page 27)  
Members \$65 Nonmembers \$150
- ISO 15190** – Medical laboratories – Requirements for safety (page 18)  
Members \$150 Nonmembers \$200

**Members \$175 Nonmembers \$400**

### CLIA Collection (SC11-L)

The documents in this collection include a group of four standards and guidelines selected because of their value in helping laboratorians adapt the CLIA '88 requirements to their settings. These documents include principles and definitions of internal quality control; preliminary evaluation of test methods; preparation of technical procedure manuals; and quality assurance procedures for culture media. The collection includes:

- C24-A2** – Quality Control (page 8)  
Members \$60 Nonmembers \$120
- EP10-A2** – Preliminary Evaluation (page 9)  
Members \$60 Nonmembers \$120
- GP2-A4** – Procedure Manuals (page 10)  
Members \$85 Nonmembers \$200
- M22-A3** – Media QC (page 14)  
Members \$60 Nonmembers \$150

**Members \$150 Nonmembers \$300**

### Coagulation (SC12-L)

This collection features procedures for collecting, transporting, and storing blood samples for coagulation testing, and reporting of test results and precautions. The volume contains general guidelines for performing the one-stage PT, APTT, and fibrinogen assay in the clinical laboratory. Included in the collection are:

- H21-A4** – Coagulation Specimens (page 11)  
Members \$85 Nonmembers \$200
- H30-A2** – Fibrinogen (page 11)  
Members \$60 Nonmembers \$120
- H47-A** – One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test (page 12)  
Members \$50 Nonmembers \$100

**Members \$85 Nonmembers \$185**

### Laboratory Information Systems (SC14-L)

This collection of former ASTM standards provides a wide variety of information relating to clinical laboratory computer systems. Some included documents are of general interest as reference sources; others represent specifications of primary importance to instrument manufacturers. The collection includes:

- LIS1-A** – Standard Specification for Low-Level Protocol to Transfer Messages Between Clinical Laboratory Instruments and Computer Systems (page 7)  
Members \$65 Nonmembers \$120
- LIS2-A2** – Specification for Transferring Information Between Clinical Laboratory Instruments and Information Systems (page 7)  
Members \$65 Nonmembers \$120
- LIS3-A** – Standard Guide for Selection of a Clinical Laboratory Information Management System (page 7)  
Members \$60 Nonmembers \$120

**LIS4-A** – Standard Guide for Documentation of Clinical Laboratory Computer Systems (page 7)  
Members \$60 Nonmembers \$120

**LIS5-A** – Standard Specification for Transferring Clinical Observations Between Independent Computer Systems (page 7)  
Members \$60 Nonmembers \$120

**LIS6-A** – Standard Practice for Reporting Reliability of Clinical Laboratory Information Systems (page 7)  
Members \$60 Nonmembers \$120

**LIS7-A** – Standard Specification for Use of Bar Codes on Specimen Tubes in the Clinical Laboratory (page 7)  
Members \$60 Nonmembers \$120

**LIS8-A** – Standard Guide for Functional Requirements of Clinical Laboratory Information Management Systems (page 7)  
Members \$60 Nonmembers \$120

**LIS9-A** – Standard Guide for Coordination of Clinical Laboratory Services within the Electronic Health Record Environment and Networked Architectures (page 7)  
Members \$60 Nonmembers \$120

**Members \$250 Nonmembers \$500**

## Technical Laboratory Management (SC15-L)

This collection contains a series of documents specifically designed to assist in technical laboratory management. These standards and guidelines include requirements for reagent grade water and methods to monitor water quality; principles and definitions of internal quality control; protocol for determining reference intervals; recommendations on writing procedure manuals; procedure for the handling and transport of specimens; and guidelines for handling and processing specimens. The collection includes:

**C3-P4** – Reagent Water (page 8)  
Members \$60 Nonmembers \$120

**C24-A2** – Quality Control (page 8)  
Members \$60 Nonmembers \$120

**C28-A2** – Reference Intervals (page 8)  
Members \$60 Nonmembers \$120

**EP10-A2** – Preliminary Evaluation (page 9)  
Members \$60 Nonmembers \$120

**GP2-A4** – Procedure Manuals (page 10)  
Members \$85 Nonmembers \$200

**H18-A3** – Handling and Processing (page 11)  
Members \$60 Nonmembers \$120

**Members \$185 Nonmembers \$410**

## Administrative Laboratory Management (SC16-L)

This collection is designed specifically to assist laboratory managers in effective laboratory operations and training. These standards and guidelines include recommendations for inventory control systems; choosing a referral laboratory; establishing a workable cost accounting system; designing a laboratory; developing new data management systems; developing a training verification program; and implementing a quality system model. This collection includes:

**GP9-A** – Referral Laboratory (page 10)  
Members \$50 Nonmembers \$100

**GP11-A** – Cost Accounting (page 10)  
Members \$60 Nonmembers \$120

**GP18-A** – Laboratory Design (page 10)  
Members \$50 Nonmembers \$100

**GP19-A2** – Laboratory Instruments and Data Management Systems (page 7)  
Members \$60 Nonmembers \$120

**GP21-A2** – Training and Competence Assessment (page 10)  
Members \$50 Nonmembers \$100

**GP26-A3** – Laboratory Services (page 10)  
Members \$85 Nonmembers \$200

**Members \$200 Nonmembers \$460**

## Point-of-Care Testing (SC17-L)

The Point-of-Care Testing collection provides guidance for laboratorians and other health professionals involved in point-of-care testing (POCT). The guidelines in this collection provide recommendations used in establishing a POCT program and procedures for point-of-care testing including quality control and calibration; skin puncture; ancillary glucose testing; and the design, preparation, and maintenance of technical procedure manuals. The collection contains:

**AST2-A** – *In Vitro* Diagnostic (page 16)  
Members \$60 Nonmembers \$150

**AST3-A** – Wellness Testing (page 16)  
Members \$50 Nonmembers \$100

**C30-A2** – Blood Glucose Testing (page 8)  
Members \$60 Nonmembers \$120

**GP2-A4** – Procedure Manuals (page 10)  
Members \$85 Nonmembers \$200

**GP16-A2** – Routine Urinalysis (page 10)  
Members \$60 Nonmembers \$120

**H4-A5** – Capillary (page 11)  
Members \$60 Nonmembers \$120

**POCT1-A** – Connectivity (page 16)  
Members \$100 Nonmembers \$150

**Members \$265 Nonmembers \$545**

## Body Fluid and Tissue Specimen Collection (SC18-L)

This collection provides guidelines for the collection of specimens for sweat testing, Papanicolaou smears, routine urinalysis, and fine needle aspiration biopsy (FNAB). Specimen transport requirements, container specifications, and safety are also included. The collection contains:

**GP15-A2** – Papanicolaou Technique (page 10)  
Members \$60 Nonmembers \$120

**GP20-A2** – Fine Needle Techniques (page 10)  
Members \$50 Nonmembers \$100

**GP23-A** – Nongynecologic Specimens (page 10)  
Members \$60 Nonmembers \$120

**M29-A3** – Protection of Laboratory Workers (page 14)  
Members \$100 Nonmembers \$200

**Members \$150 Nonmembers \$280**

## Blood Collection Centers (SC20-L)

This specialty collection brings together documents that deal with the collection, processing, and handling of blood specimens for laboratory testing. This collection can be used to establish a blood collection and processing training manual. Specimen collection by venipuncture and skin puncture along with safety guidelines, and needlestick and sharps prevention are included. Documents included are:

**H3-A5** – Venipuncture (page 11)  
Members \$85 Nonmembers \$200

**H4-A5** – Capillary (page 11)  
Members \$60 Nonmembers \$120

**H18-A3** – Handling and Processing (page 11)  
Members \$60 Nonmembers \$120

**H21-A4** – Coagulation Specimens (page 11)  
Members \$85 Nonmembers \$200

**LA4-A4** – Newborn Screening (page 13)  
Members \$60 Nonmembers \$120

**M29-A3** – Protection of Laboratory Workers (page 14)  
Members \$100 Nonmembers \$200

**X3-R** – Needlestick (page 27)  
Members \$65 Nonmembers \$150

**Members \$240 Nonmembers \$480**

## Susceptibility Testing (SC21-L)

This group of documents allows the microbiology laboratory to access in one volume all consensus documents relating to susceptibility testing. The collection addresses disk, dilution, and bactericidal testing procedures, including interpretive tables for antimicrobial, antifungal, and veterinary susceptibility tests. The collection includes:

**M2-A8** – Disk Susceptibility Tests (page 13)  
Members \$150 Nonmembers \$275

**M7-A6** – Aerobic Susceptibility Testing (page 13)  
Members \$150 Nonmembers \$275

**M11-A6** – Anaerobic Susceptibility Testing (page 13)  
Members \$85 Nonmembers \$200

**M21-A** – Serum Bactericidal Test (page 13)  
Members \$60 Nonmembers \$120

**M23-A2** – Test Development (page 14)  
Members \$150 Nonmembers \$250

**M26-A** – Bactericidal Activity (page 14)  
Members \$60 Nonmembers \$120

**M27-A2** – Antifungal Reference Method (page 14)  
Members \$60 Nonmembers \$120

**M31-A2** – Veterinary Antimicrobial (page 14)  
Members \$60 Nonmembers \$120

**M38-A** – Filamentous Fungi (page 15)  
Members \$60 Nonmembers \$120

**M39-A** – Analysis and Presentation (page 15)  
Members \$60 Nonmembers \$120

**M100-S15** – Susceptibility Testing Supplement (page 15)  
Members \$85 Nonmembers \$200

**Members \$465 Nonmembers \$880**

## General Microbiology (SC22-L)

This new collection provides guidance for the microbiologist performing aerobic or anaerobic antimicrobial susceptibility testing and routine quality assurance of commercially prepared culture media. Guidance is included for protection from infectious diseases transmitted by blood, body fluids, and tissue and instrument biohazards. The collection includes:

**M2-A8** – Disk Susceptibility Tests (page 13)  
Members \$150 Nonmembers \$275

**M7-A6** – Aerobic Susceptibility Testing (page 13)  
Members \$150 Nonmembers \$275

**M11-A6** – Anaerobic Susceptibility Testing (page 13)  
Members \$85 Nonmembers \$200

**M15-A** – Parasitic Diseases (page 13)  
Members \$60 Nonmembers \$120

**M22-A3** – Media QC (page 14)  
Members \$60 Nonmembers \$150

**M29-A3** – Protection of Laboratory Workers (page 14)  
Members \$100 Nonmembers \$200

**M35-A** – Rapid Identification (page 14)  
Members \$60 Nonmembers \$120

**M100-S15** – Susceptibility Testing Supplement (page 15)  
Members \$85 Nonmembers \$200

**Members \$375 Nonmembers \$725**

**Flow Cytometry** (SC23-L)

This collection contains a series of documents specifically designed to guide laboratorians in flow cytometric analyses. These documents include recommendations for the performance of immunophenotyping leukemias and lymphomas and performance of reticulocyte counting by flow cytometry. Guidelines for establishing quality assurance procedures for immunophenotyping lymphocytes by flow cytometry are also included in this collection.

The collection includes:

**H42-A** – Flow Cytometry (page 12)

Members \$50 Nonmembers \$100

**H43-A** – Leukemia Immunophenotyping (page 12)

Members \$50 Nonmembers \$100

**H44-A2** – Reticulocyte Counting (page 12)

Members \$50 Nonmembers \$100

**H52-A** – Fetal Red Cell Detection (page 12)

Members \$60 Nonmembers \$120

**M29-A3** – Protection of Laboratory Workers (page 14)

Members \$100 Nonmembers \$200

**Members \$160 Nonmembers \$330**

**Quality Series** (SC24-L)

This collection contains a series of documents intended for healthcare managers who wish to improve their programs through quality management activities. Guidelines are for statistical quality control, training verification, continuous quality improvement, a quality system model, and using proficiency testing. The collection includes:

**ISO 15189** – Medical laboratories – Particular requirements for quality and competence (page 18)

Members \$150 Nonmembers \$200

**GP2-A4** – Procedure Manuals (page 10)

Members \$85 Nonmembers \$200

**GP21-A2** – Training and Competence Assessment (page 10)

Members \$50 Nonmembers \$100

**GP22-A2** – Continuous Quality Improvement (page 10)

Members \$85 Nonmembers \$200

**GP26-A3** – Laboratory Services (page 10)

Members \$85 Nonmembers \$200

**H51-A2** – A Quality Management System Model for Health Care (page 6)

Members \$85 Nonmembers \$200

**HS4-A** – Respiratory Services (page 6)

Members \$50 Nonmembers \$100

**HS5-A** – Medical Imaging Services (page 6)

Members \$50 Nonmembers \$100

**HS10-A** – Inpatient Medication Use (page 6)

Members \$50 Nonmembers \$100

**Members \$370 Nonmembers \$730**

**Molecular Methods** (SC25-L)

The documents in this collection provide guidance on the performance, quality assurance, and application of various molecular methods and formats used for detection of genetic diseases/disorders; gene rearrangements and translocations; and infectious diseases. The collection includes:

**MM1-A** – Molecular Genetics (page 15)

Members \$60 Nonmembers \$120

**MM2-A2** – Molecular Hematology (page 15)

Members \$60 Nonmembers \$120

**MM3-P2** – Molecular Microbiology (page 15)

Members \$60 Nonmembers \$120

**MM4-A** – Immunocytochemistry (page 15)

Members \$60 Nonmembers \$120

**MM5-A** – PCR-Based Assays (page 15)

Members \$60 Nonmembers \$120

**MM6-A** – Infectious Diseases (page 16)

Members \$60 Nonmembers \$120

**MM7-A** – FISH Methods for Medical Genetics (page 16)

Members \$60 Nonmembers \$120

**MM9-A** – Nucleic Acid Sequencing (page 16)

Members \$60 Nonmembers \$120

**MM14-A** – Proficiency Testing (page 16)

Members \$60 Nonmembers \$120

**Members \$270 Nonmembers \$570**

**Veterinary Microbiology** (SC26-L)

This collection provides guidance for the veterinary professional on quality assurance procedures for culture media; protection from infectious diseases transmitted by blood, body fluids, and tissue; veterinary susceptibility tests; and detection of antibodies that cause Lyme disease. The collection includes:

**M22-A3** – Media QC (page 14)

Members \$60 Nonmembers \$150

**M29-A3** – Protection of Laboratory Workers (page 14)

Members \$100 Nonmembers \$200

**M31-A2** – Veterinary Antimicrobial Susceptibility Tests (page 14)

Members \$60 Nonmembers \$120

**M34-A** – Lyme Disease (page 14)

Members \$60 Nonmembers \$120

**M37-A2** – Veterinary Test Development (page 14)

Members \$60 Nonmembers \$120

**M42-P** – Disk AST Aquatic Animals (page 15)

Members \$60 Nonmembers \$120

**M49-P** – Dilution AST Aquatic Animals (page 15)

Members \$60 Nonmembers \$120

**Members \$230 Nonmembers \$450**

*Includes CD ROM***Laboratory Automation** (SC27-L)

This collection of interrelated automation standards was developed to allow customers (laboratories) and vendors to enjoy products that function together (with Plug-N-Play capabilities), and buyers and suppliers to agree on a format for laboratory automation systems. This collection contains:

**AUTO1-A** – Specimen Container/Specimen Carrier (page 6)

Members \$50 Nonmembers \$100

**AUTO2-A** – Specimen Identification (page 6)

Members \$50 Nonmembers \$100

**AUTO3-A** – Systems Communications (page 6)

Members \$50 Nonmembers \$100

**AUTO4-A** – Systems Status (page 6)

Members \$50 Nonmembers \$100

**AUTO5-A** – Electromechanical Interfaces (page 7)

Members \$50 Nonmembers \$100

**GP18-A** – Laboratory Design (page 10)

Members \$50 Nonmembers \$100

**GP19-A2** – Laboratory Instruments and Data Management Systems (page 7)

Members \$60 Nonmembers \$120

**POCT1-A** – Connectivity (page 16)

Members \$100 Nonmembers \$150

**Members \$350 Nonmembers \$650**

**Patient Assessment and Requisition** (SC28-L)

This specialty collection is designed to provide information for respiratory service professionals and other healthcare practitioners responsible for the collection of samples for arterial blood gas and pH determination and related measurements. The documents in this collection focus on preanalyzed variables related to these measurements.

**C31-A2** – Ionized Calcium (page 8)

Members \$60 Nonmembers \$120

**C46-A** – Blood Gas and pH Analysis (page 8)

Members \$60 Nonmembers \$120

**GP15-A2** – Papanicolaou Technique (page 10)

Members \$60 Nonmembers \$120

**H11-A4** – Arterial Collection (page 9)

Members \$60 Nonmembers \$120

**LA4-A4** – Newborn Screening (page 13)

Members \$60 Nonmembers \$120

**Member \$150 Nonmember \$320**

**Quality Basics** (SC30-L)

This collection provides medical laboratories with specific tactics for implementing quality guidelines.

**ISO 15189** – Medical laboratories – Particular requirements for quality and competence (page 18)

Members \$150 Nonmembers \$200

**GP26-A3** – Laboratory Services (page 10)

Members \$85 Nonmembers \$200

**HS1-A2** – A Quality Management System Model for Health Care (page 6)

Members \$85 Nonmembers \$200

**GP22-A2** – Continuous Quality Improvement (page 10)

Members \$85 Nonmembers \$200

**Members \$190 Nonmembers \$350**

**Regulatory Compliance** (SC31-L)

This collection contains a series of documents that will help laboratories comply with regulatory requirements.

**C24-A2** – Quality Control (page 8)

Members \$60 Nonmembers \$120

**C28-A2** – Reference Intervals (page 8)

Members \$60 Nonmembers \$120

**GP2-A4** – Procedure Manuals (page 10)

Members \$85 Nonmembers \$200

**GP22-A2** – Continuous Quality Improvement (page 10)

Members \$85 Nonmembers \$200

**GP26-A3** – Laboratory Services (page 10)

Members \$85 Nonmembers \$200

**GP27-A** – Proficiency Testing (page 11)

Members \$50 Nonmembers \$100

**H3-A5** – Venipuncture (page 11)

Members \$85 Nonmembers \$200

**H21-A4** – Specimen Coagulation (page 11)

Members \$85 Nonmembers \$200

**H47-A** – One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test (page 12)

Members \$50 Nonmembers \$100

**M22-A3** – Media QC (page 14)

Members \$60 Nonmembers \$150

**M29-A3** – Protection of Laboratory Workers (page 14)

Members \$100 Nonmembers \$200

**Members \$375 Nonmembers \$850**

Save up to 50% off individual document list prices.

Preview sample pages and place orders at [www.clsi.org](http://www.clsi.org)

# Standards and Guidelines

**A** = Approved standard or guideline

**P** = Proposed standard or guideline

**R** = Report

**FDA** = The U.S. Food and Drug Administration (FDA) has evaluated and recognized these approved-level consensus standards for use in satisfying a regulatory requirement.

 = A document for national application.

\* American National Standards have been approved by the American National Standards Institute (ANSI). Clinical and Laboratory Standards Institute submits selected standards as candidate American National Standards when such status will enhance their national or international usefulness.

## HEALTHCARE SERVICES

### **A** A Quality Management System Model for Health Care; Approved Guideline – Second Edition (HS1-A2) 2004

This document provides a model for healthcare services that will assist with implementation and maintenance of effective quality management systems. (See related publications HS4-A, HS5-A, HS10-A, and GP26-A2.)

**Members \$85 Nonmembers \$200**

Chairholder: Lucia M. Berte, MA, MT (ASCP), SBB, DIM, CQA(ASQ)CQMgr  
Quality Systems Consultant

### **A** Provider-Performed Microscopy Testing; Approved Guideline (HS2-A) 2003

This guideline provides recommendations for provider-performed microscopy (PPM) procedures in settings outside the traditional clinical laboratory, such as physicians' offices, outpatient clinics, public health clinics, health maintenance organizations, and medical training programs. These consensus recommendations focus on producing accurate diagnostic information from microscopy procedures as an adjunct to clinical laboratory testing.

**Members \$50 Nonmembers \$100**

Chairholder: Mina L. Harkins, MT(ASCP)  
Quest Diagnostics, Inc.

### **A** Pulse Oximetry; Approved Guideline (HS3-A) 2005

Pulse oximetry is a widely used device for the clinical assessment of arterial oxygenation and pulse rate. The clinical applications, quality assessment, and limitations are discussed in this guideline.

**Members \$50 Nonmembers \$100**

Chairholder: Judy Dye, MA  
University of Arizona Medical Center

### **A** Application of a Quality System Model for Respiratory Services; Approved Guideline (HS4-A) 2002

This document provides a model for providers of respiratory services that will assist with implementation and maintenance of an effective quality system.

**Members \$50 Nonmembers \$100**

Chairholder: Susan Blonshine, RRT, RPFT, FAARC  
Tech Ed

This document is intended for use with HS1 when developing a quality system for the clinical laboratory.

### **A** Application of a Quality System Model for Medical Imaging Services; Approved Guideline (HS5-A) 2002

This guideline provides the necessary background information and infrastructure to develop a quality system that defines a structure for a comprehensive, systematic approach to build quality into the imaging services processes, assess its performance, and implement quality improvements. Individual service areas, such as diagnostic radiology, CT, ultrasound, interventional radiology, magnetic resonance imaging (MRI), mammography, and nuclear medicine, will benefit from applying this model to their respective operations. To provide a practical example of how a quality system is developed and implemented, suggestions for diagnostic radiology are included.

**Members \$50 Nonmembers \$100**

Chairholder: Judy Dye, MA  
University of Arizona Medical Center

This document is intended for use with HS1 when developing a quality system for the clinical laboratory.

### **A** Studies to Evaluate Patient Outcomes; Approved Guideline (HS6-A) 2004

This guideline describes the essential issues in planning outcomes research including resources needed, formulating a research question, validity and sources of error, feasibility, and ethical issues; addresses the design and implementation of a patient outcomes research plan including study design, study subjects, measurements, interventions, and analysis; summarizes recommendations for reporting patient outcomes research; and includes definitions, references, and resources for those interested in planning, conducting, and using patient outcomes research.

**Members \$50 Nonmembers \$100**

Chairholder: D. Joe Boone, PhD  
Centers for Disease Control and Prevention

### **A** Application of a Quality System Model for Inpatient Medication Use; Approved Guideline (HS10-A) 2004

This document describes the path of workflow for inpatient medication use, which is defined as the sequential processes in preservice, service, and postservice activities that transform a physician's medication order into an administered medication. Pharmacy-specific information and examples for the path of workflow and quality system essentials are provided.

**Members \$50 Nonmembers \$100**

Chairholder: Steven P. Gray, MS, DAHCE, FAAHC  
Superior Consultant Company

### **P** A Model for Managing Medical Device Hazards and Recalls; Proposed Guideline (HS11-P) 2005

This document provides a framework for healthcare delivery organizations to respond to externally generated notifications of medical device hazards and recalls while focusing on the quality constructs of process control, occurrence management, and process improvement.

**Members \$50 Nonmembers \$100**

Chairholder: Peggy Prinz Luebbert, MS, MT(ASCP), CIC  
Alegent Health

## AUTOMATION AND INFORMATICS

### **A** Laboratory Automation: Specimen Container/Specimen Carrier; Approved Standard (AUTO1-A) 2000

This document provides standards for the design and manufacture of specimen containers and carriers used for collecting and processing liquid samples, such as blood and urine, for clinical testing in laboratory automation systems.

**Members \$50 Nonmembers \$100**

Chairholder: Paul J. Orsulak, PhD  
VA North Texas Health Care System



### **A** Laboratory Automation: Bar Codes for Specimen Container Identification; Approved Standard (AUTO2-A) 2000

This document provides specifications for use of linear bar codes on specimen container tubes in the clinical laboratory and for use on laboratory automation systems.

**Members \$50 Nonmembers \$100**

Chairholder: David Chou, MD  
University of Washington Medical Center



### **A** Laboratory Automation: Communications with Automated Clinical Laboratory Systems, Instruments, Devices, and Information Systems; Approved Standard (AUTO3-A) 2000

This document provides standards to facilitate accurate and timely electronic exchange of data and information between the automated laboratory elements. *AUTO3 has adapted and incorporated HL7 triggers, messages, and segments, with permission from Health Level Seven (HL7).*

**Members \$50 Nonmembers \$100**

Chairholder: Charles D. Hawker, PhD  
ARUP Laboratories



### **A** Laboratory Automation: Systems Operational Requirements, Characteristics, and Information Elements; Approved Standard (AUTO4-A) 2001

This document describes operational requirements, characteristics, and required information elements of clinical laboratory automation systems. This information is used to determine the status of a clinical specimen within the clinical laboratory automation system, as well as the status of the actual components of the clinical laboratory automation system.

**Members \$50 Nonmembers \$100**

Chairholder: Russell H. Tomar, MD  
Cook County Hospital



**A** **Laboratory Automation: Electromechanical Interfaces; Approved Standard (AUT05-A) 2001**

This document provides standards for the development of an electromechanical interface between instruments and specimen processing and handling devices used in automated laboratory testing procedures.

**Members \$50 Nonmembers \$100**

Chairholder: Richard A. McPherson, MD  
Medical College of Virginia Hospitals



**A** **Laboratory Automation: Data Content for Specimen Identification; Approved Standard (AUT07-A) 2004**

This document provides specifications for the content of linear bar codes on specimen container tubes in the clinical laboratory and for use on laboratory automation systems.

**Members \$150 Nonmembers \$250**

Chairholder: Randy R. Davis  
Dade Behring Inc.

**P** **Protocols to Validate Laboratory Information Systems; Proposed Guideline (AUT08-P) 2005**

This document provides guidance for developing a protocol for validation of the Laboratory Information System (LIS) as well as protocols for assessing the dependability of the LIS when storing, retrieving, and transmitting data.

**Members \$50 Nonmembers \$100**

Chairholder: Sandy Pearson, MT(ASCP)  
Center for Medicare & Medicaid Services

**P** **Remote Access to Clinical Laboratory Diagnostic Devices via the Internet; Proposed Standard (AUT09-P) 2005**

This document provides a standard communication protocol for instrument system vendors, device manufacturers, and hospital administrators to allow remote connections to laboratory diagnostic devices. The remote connections can be used to monitor instruments' subsystems; collect diagnostics data for remote system troubleshooting; and collect data for electronic inventory management.

**Members \$50 Nonmembers \$100**

Chairholder: Randy R. Davis  
Dade Behring Inc.

**A** **Laboratory Instruments and Data Management Systems: Design of Software User Interfaces and End-User Software Systems Validation, Operation, and Monitoring; Approved Guideline – Second Edition (GP19-A2) 2003**

This document identifies important factors that designers and laboratory managers should consider when developing new software-driven systems and selecting software user interfaces. Also included are simple rules to help prepare validation protocols for assessing the functionality and dependability of software.

**Members: \$60 Nonmembers: \$120**

Chairholder: Andrzej J. Knafel, PhD  
Roche Instrument Center AG



**A** **Standard Specification for Low-Level Protocol to Transfer Messages Between Clinical Laboratory Instruments and Computer Systems (LIS1-A) 2003**

This specification describes the electronic transmission of digital information between clinical laboratory instruments (those that measure one or more parameters from one or multiple samples) and computer systems (those that are configured to accept instrument results for further processing, storage, reporting, or manipulation).

**Members: \$65 Nonmembers: \$120**

**A** **Specification for Transferring Information Between Clinical Laboratory Instruments and Information Systems; Approved Standard – Second Edition (LIS2-A2) 2004**

This document covers the two-way digital transmission of remote requests and results between clinical laboratory instruments and information systems. It enables any two such systems to establish a logical link for communicating text to send result, request, or demographic information in a standardized and interpretable form.

**Members \$65 Nonmembers \$120**

Chairholders: Rodney S. Markin, MD, PhD  
University of Nebraska Medical Center, and  
Andrzej J. Knafel, PhD  
Roche Instrument Center AG

**A** **Standard Guide for Selection of a Clinical Laboratory Information Management System (LIS3-A) 2003**

This guide covers the selection, purchase, use, enhancement, and updating of computer technology supplied by a vendor as a complete system in the clinical laboratory. The purpose of the guide is to assist hospitals, clinics, and independent laboratories through the entire automation project in order to minimize the risks and maximize the benefits. It also includes checklists of items and design aids to be considered at each stage of planning to assist in carrying out the project.

**Members: \$60 Nonmembers: \$120**

**A** **Standard Guide for Documentation of Clinical Laboratory Computer Systems (LIS4-A) 2003**

This guide covers documentation (defined as the information needed to install, use, maintain, or modify the system) for a computer system operating in a clinical laboratory.

**Members: \$60 Nonmembers: \$120**

**A** **Standard Specification for Transferring Clinical Observations Between Independent Computer Systems (LIS5-A) 2003**

This specification details how clinical observations can be transferred between independent computer systems.

**Members: \$60 Nonmembers: \$120**

**A** **Standard Practice for Reporting Reliability of Clinical Laboratory Information Systems (LIS6-A) 2003**

This practice describes a system for collecting data, maintaining records, and reporting on the reliability of operating clinical laboratory computer systems. The reliability measure will be achieved by documenting the number, severity, cause, impact, and duration of the failures that a system experiences. This practice can be implemented with paper forms or computer records.

**Members: \$60 Nonmembers: \$120**

**A** **Standard Specification for Use of Bar Codes on Specimen Tubes in the Clinical Laboratory (LIS7-A) 2003**

This specification identifies the way bar-coded sample identification labels are applied to clinical specimen containers. It documents the form, placement, and content of bar-code labels on specimen tubes that are used on clinical laboratory analyzers. It enables Laboratory Information System vendors to produce reliable bar-coded symbols that are readable by any complying clinical laboratory analyzer vendor.

**Members: \$60 Nonmembers: \$120**

**A** **Standard Guide for Functional Requirements of Clinical Laboratory Information Management Systems (LIS8-A) 2003**

This guide covers the capabilities needed for a logical structure of a Clinical Laboratory Information Management System (CLIMS). It was written so that both vendors/developers of CLIMS and laboratory managers would have a common understanding of the requirements and logical structure of a laboratory data system. This guide will also provide more uniformity in the way that requirements are expressed from one laboratory to another.

**Members: \$60 Nonmembers: \$120**

**A** **Standard Guide for Coordination of Clinical Laboratory Services within the Electronic Health Record Environment and Networked Architectures (LIS9-A) 2003**

This guide covers the process of defining and documenting the capabilities, sources, and pathways of data exchange within a given network architecture of a Health Information Network (HIN) serving a set of constituents.

**Members: \$60 Nonmembers: \$120**

Currently, the newly adopted LIS documents are not part of the member benefits package. As documents are revised through our consensus process, they will be distributed to members according to membership category.

## CLINICAL CHEMISTRY AND TOXICOLOGY

### **A** Glucose Monitoring in Settings Without Laboratory Support; Approved Guideline – Second Edition (AST4-A2) 2005

**NEW**

This document contains guidelines for performance of point-of-care (POC) glucose monitoring systems that stress quality control, training, and administrative responsibility.

**Members: \$60 Nonmembers: \$120**

Chairholder: Louis J. Dunka, Jr., PhD, FACB  
LifeScan, Inc.

### **P** Preparation and Testing of Reagent Water in the Clinical Laboratory; Proposed Guideline – Fourth Edition (C3-P4) 2005

**NEW**

This document provides guidelines on water purified for clinical laboratory use; methods for monitoring water quality and testing for specific contaminants; and water system design considerations.

**Members: \$60 Nonmembers: \$120**

Chairholder: W. Gregory Miller, PhD  
Virginia Commonwealth University

### **A** Statistical Quality Control for Quantitative Measurements: Principles and Definitions; Approved Guideline – Second Edition (C24-A2) 1999

This guideline provides definitions of analytical intervals; plans for quality control procedures; and guidance for quality control applications.

**Members: \$60 Nonmembers: \$120**

Chairholder: James O. Westgard, PhD  
University of Wisconsin

### **A** How to Define and Determine Reference Intervals in the Clinical Laboratory; Approved Guideline – Second Edition (C28-A2) 2000

This document provides guidance for determining reference values and reference intervals for quantitative clinical laboratory tests.

**Members: \$60 Nonmembers: \$120**

Chairholder: Basil T. Doumas, PhD  
Medical College of Wisconsin

### **A** Standardization of Sodium and Potassium Ion-Selective Electrode Systems to the Flame Photometric Reference Method; Approved Standard – Second Edition (C29-A2) 2000

**REAFFIRMED  
JUNE 2003**

This standard contains recommendations for the expression of results of ion-selective electrode measurement of sodium and potassium ion activities in undiluted serum, plasma, or whole blood in clinical practice.

**Members: \$60 Nonmembers: \$120**

Chairholder: Paul D'Orazio, PhD  
Instrumentation Laboratory

### **A** Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline – Second Edition (C30-A2) 2002

This document provides guidance for performing point-of-care blood glucose tests, with an emphasis on quality control, training, and administrative responsibility.

**Members: \$60 Nonmembers: \$120**

Chairholder: David B. Sacks, MD  
Brigham and Women's Hospital and Harvard Medical School

### **A** Ionized Calcium Determinations: Pre-collection Variables, Specimen Choice, Collection, and Handling; Approved Guideline – Second Edition (C31-A2) 2001

This document addresses preanalytical considerations – such as patient condition, specimen choice, collection, and handling – that can influence accuracy and clinical utility of ionized calcium measurements.

**Members: \$60 Nonmembers: \$120**

Chairholder: Paul D'Orazio, PhD  
Instrumentation Laboratory

### **A** Sweat Testing: Sample Collection and Quantitative Analysis; Approved Guideline – Second Edition (C34-A2) 2000

This guideline describes sweat stimulation, collection, and the quantitative analysis of sweat chloride and sodium with an emphasis on avoiding evaporation and contamination. Quality control issues and possible sources of error associated with sweat testing are discussed.

**Members: \$60 Nonmembers: \$120**

Chairholder: Vicky A. LeGrys, DrA, MT(ASCP)  
University of North Carolina School of Medicine

### **A** Preparation and Validation of Commutable Frozen Human Serum Pools as Secondary Reference Materials for Cholesterol Measurement Procedures; Approved Guideline (C37-A) 1999

This guideline details procedures for the manufacture and evaluation of human serum pools for cholesterol measurement.

**Members: \$60 Nonmembers: \$120**

Chairholder: Gary L. Myers, PhD  
Centers for Disease Control and Prevention

### **A** Control of Preanalytical Variation in Trace Element Determinations; Approved Guideline (C38-A) 1997

This document contains guidelines for patient preparation, specimen collection, transport, and processing for the measurement of trace elements in a variety of biological matrices.

**Members: \$60 Nonmembers: \$120**

Chairholder: Gillian Lockitch, MD, FRCPC  
British Columbia's Children's Hospital

### **A** A Designated Comparison Method for the Measurement of Ionized Calcium in Serum; Approved Standard (C39-A) 2000

This document describes a designated comparison method to standardize the ionized calcium measurements made by ion-selective electrode (ISE) potentiometry. This system can be used to assign ionized calcium concentrations to a commercially available, serum-based material to improve the traceability and transferability of results for ionized calcium measurements in the clinical laboratory.

**Members: \$60 Nonmembers: \$120**

Co-Chairholders: Paul D'Orazio, PhD,  
Instrumentation Laboratory, and Gary A.  
Graham, PhD, DABCC, Ortho-Clinical Diagnostics

### **A** Analytical Procedures for the Determination of Lead in Blood and Urine; Approved Guideline (C40-A) 2001

This document offers guidance for the measurement of lead in blood and urine, including specimen collection, measurement by GFAAS and ASV, quality assurance, and quality control.

**Members: \$60 Nonmembers: \$120**

Chairholder: Patrick J. Parsons, PhD, CChem, FRSC  
New York State Department of Health

### **A** Erythrocyte Protoporphyrin Testing; Approved Guideline (C42-A) 1996

**REAFFIRMED  
SEPT. 2001**

This document contains recommended guidelines for the measurement, reporting, and interpretation of erythrocyte protoporphyrin using hematofluorometric and extraction measurement methods.

**Members \$50 Nonmembers \$100**

Chairholder: Noel V. Stanton, MS  
Wisconsin State Laboratory of Hygiene

### **A** Gas Chromatography/Mass Spectrometry (GC/MS) Confirmation of Drugs; Approved Guideline (C43-A) 2002

This document provides guidance for establishing uniform practices necessary for producing quality data for quantitation and identification of a drug or drug metabolite using the GC/MS method; specific quality assurance criteria for maintaining and documenting optimal instrument performance are also presented.

**Members: \$60 Nonmembers: \$120**

Chairholder: Larry D. Bowers, PhD, DABCC  
U.S. Anti-Doping Agency

### **A** Harmonization of Glycohemoglobin Measurements; Approved Guideline (C44-A) 2002

This document describes an established program to harmonize glycohemoglobin (GHB) testing results among laboratories to a common, outcomes-based reference system and includes recommendations for the clinical application of harmonized GHB testing results.

**Members: \$60 Nonmembers: \$120**

Chairholder: David E. Goldstein, MD  
University of Missouri School of Medicine

### **A** Measurement of Free Thyroid Hormones; Approved Guideline (C45-A) 2004

This document addresses analytical and clinical validation of free (nonprotein-bound) thyroid hormone (FTH) measurement procedures. An NCCLS-IFCC joint project.

**Members \$60 Nonmembers \$120**

Chairholder: Linda Thienpont, PhD  
University of Ghent

### **A** Blood Gas and pH Analysis and Related Measurements; Approved Guideline (C46-A) 2001

*American National Standard.* \* This document provides clear definitions of the several quantities in current use, and provides a single source of information on appropriate specimen collection, preanalytical variables, calibration, and quality control for blood pH and gas analysis and related measurements.

**Members: \$60 Nonmembers: \$120**

Chairholder: W. Gregory Miller, PhD  
Virginia Commonwealth University

### **A** Application of Biochemical Markers of Bone Turnover in the Assessment and Monitoring of Bone Diseases; Approved Guideline (C48-A) 2004

Biochemical markers of bone turnover are increasingly used in clinical chemistry. This guideline provides information on how bone markers can be applied to facilitate and harmonize data interpretation and to help answer clinical questions in the area of bone diseases. An NCCLS-IFCC joint project.

**Members \$60 Nonmembers \$120**

*Chairholder: Hubert Vesper, PhD  
Centers for Disease Control and Prevention*

### **A** Procedures for the Collection of Arterial Blood Specimens; Approved Standard – Fourth Edition (H11-A4) 2004

*American National Standard.\** This standard describes principles for collecting, handling, and transporting arterial blood specimens. The document is aimed at reducing collection hazards and ensuring integrity of the arterial specimen.

**Members \$60 Nonmembers \$120**

*Chairholder: Susan Blonshine, BS, RRT, RPFT  
Tech Ed/AARC*

### **A** Determination of Serum Iron, Total Iron-Binding Capacity and Percent Transferrin Saturation; Approved Standard (H17-A) 1998

This document provides methods for determining serum iron and total iron-binding capacity; and describes the measurement of serum iron concentration as well as the determination of the percent saturation of transferrin with iron.

**Members: \$60 Nonmembers: \$120**

*Chairholder: Onno W. van Assendelft, MD, PhD  
Centers for Disease Control and Prevention*

### **A** Blood Alcohol Testing in the Clinical Laboratory; Approved Guideline (T/DM6-A) 1997

**REAFFIRMED  
SEPT. 2002**

This document provides technical and administrative guidance on laboratory procedures related to blood alcohol testing, including specimen collection, methods of analysis, quality assurance, and reporting of results.

**Members \$50 Nonmembers \$100**

*Chairholder: Kurt M. Dubowski, PhD  
University of Oklahoma*

**FDA**

### **A** Urine Drug Testing in the Clinical Laboratory; Approved Guideline (T/DM8-A) 1999

This guideline addresses the development of procedures for urine analysis to determine the presence of certain controlled substances. Specimen collection and processing, methods of analysis, quality assurance, and reporting of results are also described.

**Members \$50 Nonmembers \$100**

*Chairholder: M. Jeffery Shoemaker, PhD  
Pennsylvania Department of Health*

## EVALUATION PROTOCOLS

### **A** Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline – Second Edition (EP5-A2) 2004

This document provides guidance for designing an experiment to evaluate the precision performance of quantitative measurement methods; recommendations on comparing the resulting precision estimates with manufacturer's precision performance claims and determining when such comparisons are valid; as well as manufacturer's guidelines for establishing claims.

**Members \$85 Nonmembers \$200**

*Chairholder: Daniel W. Tholen, MS  
Dan Tholen Statistical Services*

### **A** Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline (EP6-A) 2003

This document provides guidance for characterizing the linearity of a method during a method evaluation; for checking linearity as part of routine quality assurance; and for determining and stating a manufacturer's claim for linear range.

**Members: \$60 Nonmembers: \$120**

*Chairholder: Daniel W. Tholen, MS  
Dan Tholen Statistical Services*

### **A** Interference Testing in Clinical Chemistry; Approved Guideline (EP7-A) 2002

This guideline provides background information, guidance, and experimental procedures for investigating, identifying, and characterizing the effects of interfering substances on clinical chemistry test results.

**Members \$85 Nonmembers \$200**

*Chairholder: Donald M. Powers, PhD  
Powers Consulting Services*

**FDA**

### **A** Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline – Second Edition (EP9-A2) 2002

This document addresses procedures for determining the bias between two clinical methods, and the design of a method comparison experiment using split patient samples and data analysis.

**Members: \$60 Nonmembers: \$120**

*Chairholder: Jan S. Krouwer, PhD  
Krouwer Consulting*

**FDA**

### **A** Preliminary Evaluation of Quantitative Clinical Laboratory Methods; Approved Guideline – Second Edition (EP10-A2) 2002

This guideline addresses experimental design and data analysis for preliminary evaluation of the performance of a measurement procedure or device. (See related publication GP10-A in General Laboratory Practices section.)

**Members: \$60 Nonmembers: \$120**

*Chairholder: Jan S. Krouwer, PhD  
Krouwer Consulting*

**FDA**

### **A** User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline (EP12-A) 2002

This document contains a protocol that optimizes the experimental design for the evaluation of qualitative tests, to better measure performance and provide a structured data analysis.

**Members: \$60 Nonmembers: \$120**

*Chairholder: Larry W. Clark, MS  
Bayer Corporation*

**FDA**

### **R** Laboratory Statistics – Standard Deviation; A Report (EP13-R) 1995

This report provides correct methods for calculating standard deviation and the means to test related software.

**Members \$60 Nonmembers \$120**

*Chairholder: Allan Louderback, PhD  
Clinical Chemistry Consultants*

### **A** Evaluation of Matrix Effects; Approved Guideline – Second Edition (EP14-A2) 2005

This document provides guidance for evaluating the bias in analyte measurements that is due to the sample matrix (physiological or artificial) when two measurement procedures are compared.

**Members: \$60 Nonmembers: \$120**

*Chairholder: Fred D. Lasky, PhD  
Genzyme Diagnostics*

### **A** User Verification of Performance for Precision and Trueness; Approved Guideline—Second Edition (EP15-A2) 2005

**NEW**

This document describes the demonstration of method precision and trueness for clinical laboratory quantitative methods utilizing a protocol designed to be completed within five working days or less.

**Members: \$60 Nonmembers: \$120**

*Chairholder: R. Neill Carey, PhD, FACB  
Peninsula Regional Medical Center*

### **A** Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline (EP17-A) 2004

This document provides guidance for determining the lower limit of detection of clinical laboratory methods, for verifying claimed limits, and for the proper use and interpretation of these limits. An NCCLS-IFCC joint project.

**Members \$60 Nonmembers \$120**

*Chairholder: Daniel W. Tholen, MS  
Dan Tholen Statistical Consulting*

### **A** Quality Management for Unit-Use Testing; Approved Guideline (EP18-A) 2002

This guideline recommends a quality management system for unit-use devices that will aid in the identification, understanding, and management of sources of error and help to ensure correct results. It is targeted for those involved in the supervision of laboratory-testing quality management, and it addresses issues related to specimen collection through reporting of test results.

**Members: \$60 Nonmembers: \$120**

*Chairholder: David L. Phillips  
LifeScan*

**FDA**

## **R** A Framework for NCCLS Evaluation Protocols; A Report (EP19-R) 2002

This document describes the different types of performance studies that are conducted to evaluate clinical assays.

**Members: \$60 Nonmembers: \$120**

Chairholder: Jan S. Krouwer, PhD  
Krouwer Consulting

## **A** Estimation of Total Analytical Error for Clinical Laboratory Methods; Approved Guideline (EP21-A) 2003

This document provides manufacturers and end users with a means to estimate total analytical error for an assay. A data collection protocol and an analysis method which can be used to judge the clinical acceptability of new methods using patient specimens are included. These tools can also monitor an assay's total analytical error by using quality control samples.

**Members: \$60 Nonmembers: \$120**

Chairholder: Jan S. Krouwer, PhD  
Krouwer Consulting

## GENERAL LABORATORY PRACTICES

### **A** Clinical Laboratory Technical Procedure Manuals; Approved Guideline – Fourth Edition (GP2-A4) 2002

This document provides guidance on development, review, approval, management, and use of policy, process, and procedure documents in the laboratory testing community. (See related publication GP21-A2.)

**Members \$85 Nonmembers \$200**

Chairholder: Lucia M. Berte, MA, MT(ASCP) SBB, DLM; CQA(ASQ)/CQMgr.  
Quality Systems Consultant

### **A** Clinical Laboratory Waste Management; Approved Guideline – Second Edition (GP5-A2) 2002



Based on U.S. regulations, this document provides guidance on safe handling and disposal of chemical, infectious, radioactive, and multihazardous wastes generated in the clinical laboratory.

**Members \$60 Nonmembers \$120**

Chairholder: Peter A. Reinhardt, MA  
University of North Carolina

### **A** Selecting and Evaluating a Referral Laboratory; Approved Guideline (GP9-A) 1998

This guideline provides an outline of reasons and criteria for choosing a referral laboratory. A checklist for evaluating potential referral laboratories is included to assist in the decision process.

**Members \$50 Nonmembers \$100**

Chairholder: Robert R. Rickert, MD  
St. Barnabas Medical Center

### **A** Assessment of the Clinical Accuracy of Laboratory Tests Using Receiver Operating Characteristic (ROC) Plots; Approved Guideline (GP10-A) 1995

REAFFIRMED  
MAY 2001

This document provides a protocol for evaluating the accuracy of a test to discriminate between two subclasses of subjects where there is some clinically relevant reason to separate them. In addition to the use of ROC plots, the importance of defining the question, selecting the sample group, and determining the "true" clinical state are emphasized. (See related publication EP10-A2 in the Evaluation Protocols section.)

**Members \$50 Nonmembers \$100**

Chairholder: Mark H. Zweig, MD  
National Institutes of Health



### **A** Basic Cost Accounting for Clinical Services; Approved Guideline (GP11-A) 1998

This document provides principles and techniques to help laboratory managers establish a workable cost-accounting system.

**Members \$60 Nonmembers \$120**

Chairholder: Eleanor M. Travers, MD, MHA  
Department of Veterans Affairs, Office of Patient Care Services

### **A** Papanicolaou Technique; Approved Guideline – Second Edition (GP15-A2) 2001

This guideline addresses procedures for cervicovaginal specimen collection, as well as the preparation, fixation, staining, and storage of Papanicolaou slides. (See related publications GP20-A2 and GP23-A.)

**Members: \$60 Nonmembers: \$120**

Chairholder: Nina Dhurandhar, MD  
Tulane University Medical Center

### **A** Urinalysis and Collection, Transportation, and Preservation of Urine Specimens; Approved Guideline – Second Edition (GP16-A2) 2001

This guideline describes routine urinalysis test procedures that address materials and equipment, macroscopic examinations, clinical analyses, and microscopic evaluations.

**Members: \$60 Nonmembers: \$120**

Chairholder: Stephen J. Sarewitz, MD  
Valley Medical Center



### **A** Clinical Laboratory Safety; Approved Guideline – Second Edition (GP17-A2) 2004

American National Standard. \* This document contains general guidelines for implementing a high-quality laboratory safety program. The framework is adaptable to any laboratory. An NCCLS-CAP joint project.

**Members \$60 Nonmembers \$120**

Chairholder: Sheila M. Woodcock, ART, MBA  
QSE Consulting

### **A** Laboratory Design; Approved Guideline (GP18-A) 1998

This guideline provides a foundation of information about laboratory design elements that can be used to help define the issues being considered when designing a laboratory.

**Members \$50 Nonmembers \$100**

Chairholder: Pennell C. Painter, PhD, FACB  
University of Tennessee Medical Center

### **A** Fine Needle Aspiration Biopsy (FNAB) Techniques; Approved Guideline – Second Edition (GP20-A2) 2003

This document contains recommended procedures for performing fine needle aspiration biopsies of superficial (palpable) and deep-seated (nonpalpable) lesions, from patient preparation through staining the smear. (See related publications GP15-A2 and GP23-A.)

**Members \$50 Nonmembers \$100**

Chairholder: Nina Dhurandhar, MD  
Tulane University Medical Center

### **A** Training and Competence Assessment; Approved Guideline – Second Edition (GP21-A2) 2004

This document provides background and recommended processes for the development of training and competence assessment programs that meet quality/regulatory objectives.

**Members \$50 Nonmembers \$100**

Chairholder: Sheila M. Woodcock, ART, MBA  
QSE Consulting

### **A** Continuous Quality Improvement: Integrating Five Key Quality System Components; Approved Guideline – Second Edition (GP22-A2) 2004

This guideline considers continuous quality improvement (CQI) as five integrated quality system components, which include Quality Planning, Quality Teamwork, Quality Monitoring, Quality Improvement, and Quality Review.

**Members \$85 Nonmembers \$200**

Chairholder: Gary B. Clark, MD, MPA  
Wellness for Life

### **A** Nongynecologic Cytologic Specimens: Collection and Cytopreparatory Techniques; Approved Guideline (GP23-A) 1999

This document provides recommended procedures for the collection, handling, transport, and processing of cytologic specimens from nongynecologic sources. (See related publications GP15-A2 and GP20-A2.)

**Members: \$60 Nonmembers: \$120**

Chairholder: Kenneth D. McClatchey, MD, DDS  
Loyola University Medical Center

### **A** Application of a Quality Management System Model for Laboratory Services; Approved Guideline – Third Edition (GP26-A3) 2004

This guideline describes the clinical laboratory's path of workflow and provides information for laboratory operations that will assist the laboratory in improving its processes and meeting government and accreditation requirements.

**Members \$85 Nonmembers \$200**

Chairholder: Lucia M. Berte, MA, MT(ASCP), SBB, DLM; CQA(ASQ)/CQMgr  
Quality System Consultant

This document is intended for use with HS1 when developing a quality system for the clinical laboratory.

**A** **Using Proficiency Testing (PT) to Improve the Clinical Laboratory; Approved Guideline (GP27-A) 1999**

REAFFIRMED  
MARCH 2002

This guideline provides assistance to laboratories in using proficiency testing as a quality improvement tool.

**Members \$50 Nonmembers \$100**

FDA

Co-chairholders: Gary B. Clark, MD, MPA, Quality Laboratory Management Associates, and Stephen J. Sarewitz, MD, Valley Medical Center

**A** **Microwave Device Use in the Histology Laboratory; Approved Guideline (GP28-A) 2005**

This document provides recommendations for reproducing the performance of microwave-accelerated procedures to prepare biological specimens in the histology laboratory.

**Members \$60 Nonmembers \$120**

Chairholder: Gary R. Login, DMD, DMSc, Harvard School of Dental Medicine

**A** **Assessment of Laboratory Tests When Proficiency Testing is Not Available; Approved Guideline (GP29-A) 2002**

This document offers methods to assess test performance when proficiency testing (PT) is not available; these methods include examples with statistical analyses. This document is intended for use by laboratory managers and testing personnel in traditional clinical laboratories as well as in point-of-care and bedside testing environments.

**Members: \$60 Nonmembers: \$120**

Chairholder: Stephen J. Sarewitz, MD, Valley Medical Center

## HEMATOLOGY

**A** **Tubes and Additives for Venous Blood Specimen Collection; Approved Standard – Fifth Edition (H1-A5) 2003**



*American National Standard.* \* This standard contains requirements for blood collection tubes and additives including heparin, EDTA, and sodium citrate.

**Members \$50 Nonmembers \$100**

FDA

Chairholder: Charles F. Arkin, MD, Lahey Clinic

**A** **Reference and Selected Procedure for the Erythrocyte Sedimentation Rate (ESR) Test; Approved Standard – Fourth Edition (H2-A4) 2000**

*American National Standard.* \* This document provides a description of the principle, materials, and procedure for reference and standardized ESR methods, as well as a procedure to evaluate routine methods, and an outline of quality control programs for the ESR test.

**Members \$50 Nonmembers \$100**

Co-chairholders: John A. Koepke, MD, Duke University Medical Center, and Onno W. van Assendelft, MD, PhD, Centers for Disease Control and Prevention

**A** **Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture; Approved Standard – Fifth Edition (H3-A5) 2003**

This document provides procedures for the collection of diagnostic specimens by venipuncture, including line draws, blood culture collection, and venipuncture in children. It also includes recommendations on order of draw.

**Members \$85 Nonmembers \$200**

FDA

Chairholder: Charles F. Arkin, MD, Lahey Clinic

See related publication X3-R on page 27.

**A** **Procedures and Devices for the Collection of Diagnostic Capillary Blood Specimens; Approved Standard – Fifth Edition (H4-A5) 2004**

This document provides a technique for the collection of diagnostic capillary blood specimens, including recommendations for collection sites and specimen handling and identification. Specifications for disposable devices used to collect, process, and transfer diagnostic capillary blood specimens are also included.

**Members \$60 Nonmembers \$120**

Chairholder: Dennis J. Ernst, MT(ASCP), Center for Phlebotomy Education

See videotape section for H4-A3-V information.

See related publication X3-R on page 27.

**A** **Procedure for Determining Packed Cell Volume by the Microhematocrit Method; Approved Standard – Third Edition (H7-A3) 2000**

*American National Standard.* \* This standard describes the standard microhematocrit method for determining packed-cell volume. It also addresses recommended materials and potential sources of error.

**Members \$60 Nonmembers \$120**

FDA

Chairholder: Onno W. van Assendelft, MD, PhD, Centers for Disease Control and Prevention

**A** **Reference and Selected Procedures for the Quantitative Determination of Hemoglobin in Blood; Approved Standard – Third Edition (H15-A3) 2000**

*American National Standard.* \* This document describes the principle, materials, and procedure for reference and standardized hemoglobin determinations. It includes specifications for secondary hemoglobin cyanide (HiCN) standards.

**Members \$50 Nonmembers \$100**

FDA

Chairholder: Onno W. van Assendelft, MD, PhD, Centers for Disease Control and Prevention

**A** **Procedures for the Handling and Processing of Blood Specimens; Approved Guideline – Third Edition (H18-A3) 2004**

This document includes criteria for preparing an optimal serum or plasma sample and for the devices used to process blood specimens.

**Members \$60 Nonmembers \$120**

FDA

Chairholder: Roger R. Calam, PhD, St. John Hospital

**A** **Reference Leukocyte Differential Count (Proportional) and Evaluation of Instrumental Methods; Approved Standard (H20-A) 1992**

This standard describes automated differential counters and establishes a reference method based on the visual (or manual) differential count for leukocyte differential counting, to which an automated or manual test method can be compared.

**Members \$50 Nonmembers \$100**

FDA

Chairholder: John A. Koepke, MD, Duke University Medical Center

**A** **Collection, Transport, and Processing of Blood Specimens for Testing Plasma-Based Coagulation Assays; Approved Guideline – Fourth Edition (H21-A4) 2003**

This guideline contains procedures for collecting, transporting, and storing blood; processing blood specimens; storing plasma for coagulation testing; and provides general recommendations for performing the tests.

**Members \$85 Nonmembers \$200**

Chairholder: Charles F. Arkin, MD, Lahey Clinic

**A** **Performance Goals for the Internal Quality Control of Multichannel Hematology Analyzers; Approved Standard (H26-A) 1996**

This document addresses performance goals for analytical accuracy and precision for multichannel hematology analyzers; the relationship of these goals to quality control systems and medical decisions; and recommendations for minimum calibrator performance and the detection of measurement errors. (See related publications H7-A3, H15-A3, and H20-A in this section.)

**Members \$50 Nonmembers \$100**

FDA

Chairholder: A. Richardson Jones, MD, Coulter Corporation

**A** **Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline – Second Edition (H30-A2) 2001**

This document provides general guidelines for performing the fibrinogen assay in the clinical laboratory. It also includes reporting of results and *in vivo* and *in vitro* conditions that may alter results. (See related publication H21-A4 in this section.)

**Members: \$60 Nonmembers: \$120**

FDA

Chairholder: Richard Marlar, PhD, Denver VA Medical Center

**P** **Calibration and Quality Control of Automated Hematology Analyzers; Proposed Standard (H38-P) 1999**

This document addresses calibration and quality control strategies for multichannel hematology analyzers; assignment of values to calibrator materials; calibration using stabilized blood controls; internal quality control; pair difference analysis; and use of the weighted moving average ( $\bar{x}_w$ ) method. An NCCLS-ICSH joint project.

**Members \$50 Nonmembers \$100**

Co-Chairholders: John A. Koepke, MD, Durham, North Carolina, and Onno W. van Assendelft, MD, PhD, Centers for Disease Control and Prevention

**A Clinical Applications of Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes; Approved Guideline (H42-A) 1998**

This document contains guidance for the immunophenotypic analysis of non-neoplastic lymphocytes by immunofluorescence-based flow cytometry; guidelines for sample and instrument quality control; and precautions for data acquisition from lymphocytes.

**Members \$50 Nonmembers \$100**

Chairholder: Michael Borowitz, MD, PhD  
The Johns Hopkins University



**A Clinical Applications of Flow Cytometry: Immunophenotyping of Leukemic Cells; Approved Guideline (H43-A) 1998**

This document provides performance guidelines for the immunophenotypic analysis of leukemic and lymphoma cells using immunofluorescence-based flow cytometry; guidelines for sample and instrument quality control; and precautions for data acquisition from leukemic cells.

**Members \$50 Nonmembers \$100**

Chairholder: Michael Borowitz, MD, PhD  
The Johns Hopkins University



**A Methods for Reticulocyte Counting (Automated Blood Cell Counters, Flow Cytometry, and Supravital Dyes); Approved Guideline – Second Edition (H44-A2) 2004**

This document provides guidance for the performance of reticulocyte counting by flow cytometry. It includes methods for determining the trueness and precision of the reticulocyte flow cytometry instrument and a recommended reference procedure. An NCCLS-ICSH joint project.

**Members \$50 Nonmembers \$100**

Chairholder: Bruce H. Davis, MD  
Maine Medical Center Research Institute

**A Performance of the Bleeding Time Test; Approved Guideline—Second Edition (H45-A2) 2005**



This document contains guidelines for performing the template bleeding time test. A descriptive list of variables that can affect the results of the test is also included.

**Members \$50 Nonmembers \$100**

Chairholder: Bruce H. Davis, MD  
Maine Medical Center Research Institute

**A One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test; Approved Guideline (H47-A) 1996**

This document provides guidelines for performing the PT and APTT tests in the clinical laboratory, for reporting results, and for identifying sources of error.

**Members \$50 Nonmembers \$100**

Chairholder: Charles F. Arkin, MD  
Boston University Medical Center



**A Point-of-Care Monitoring of Anticoagulation Therapy; Approved Guideline (H49-A) 2004**

This guideline provides guidance to users and manufacturers of point-of-care coagulation devices for monitoring of heparin and warfarin anticoagulant therapy and to ensure reliable results comparable to those obtained by routine clinical laboratory testing.

**Members \$50 Nonmembers \$100**

Chairholder: Jack E. Ansell, MD  
Boston University Medical Center

**A Assays of von Willebrand Factor Antigen and Ristocetin Cofactor Activity; Approved Guideline (H51-A) 2002**

This guideline describes appropriate test specimens, reagents and materials, methods of platelet agglutination and ELISA, preparation of reference curves, determination of reference intervals, quality control procedures, result interpretation, and sources of error for assays of von Willebrand factor antigen and ristocetin cofactor activity. A brief description of von Willebrand disease and its various subtypes is included, as well as a list of references to more comprehensive reviews of this commonly inherited and rarely acquired bleeding disorder.

**Members \$60 Nonmembers \$120**

Chairholder: Richard Marlar, PhD  
Denver VA Medical Center



**A Fetal Red Cell Detection; Approved Guideline (H52-A) 2001**

This document provides guidance for the quantitation of fetal red blood cells in blood and other biologic fluids. The performance characteristics of various flow cytometric and microscopic assays are reviewed, recommendations are made for control usage, and principles for distinction of F cells and fetal red cells are discussed.

**Members \$60 Nonmembers \$120**

Chairholder: Bruce H. Davis, MD  
Maine Medical Center

**A Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline (H54-A) 2005**



This document, published as two stand-alone guidelines, describes the use of certified plasmas to enhance performance of the prothrombin time (PT)/International Normalized Ratio (INR) system test; reviews limitations of the INR system that may occur when a manufacturer-determined ISI is used without local verification or calibration; and provides a rationale for performing local ISI verification with recommendations as to when PT calibration may be indicated. Part I is a detailed, expanded account for manufacturers and Part II is an abbreviated version useful for the clinical laboratory.

**Members \$50 Nonmembers \$100**

Chairholder: Dorothy M. Adcock, MD  
Esoterix Coagulation

**P Body Fluid Analysis for Cellular Composition; Proposed Guideline (H56-P) 2005**



This guideline provides users with recommendations for collection and transport of body fluids, numeration and identification of cellular components, and guidance for qualitative and quantitative assessment of body fluid.

**Members \$50 Nonmembers \$100**

Chairholder: Diane I. Szamosi, MA, MT(ASCP)SH  
Greiner Bio-One North America, Preanalytics

**IMMUNOLOGY AND LIGAND ASSAY**

**A Quality Assurance for the Indirect Immunofluorescence Test for Autoantibodies to Nuclear Antigen (IF-ANA); Approved Guideline (I/LA2-A) 1996**

This document addresses the criteria for immunofluorescence ANA testing, including test components, quantification of results, and classification criteria.

**Members \$50 Nonmembers \$100**

Chairholder: Robert M. Nakamura, MD  
Scripps Clinic and Research Foundation



**A Apolipoprotein Immunoassays: Development and Recommended Performance Characteristics; Approved Guideline (I/LA15-A) 1997**



This guideline describes the characterization and preparation of immunogens, antibodies, samples, and methods, and provides guidance for immunochemical testing of apolipoproteins.

**Members \$50 Nonmembers \$100**

Chairholder: Robert F. Ritchie, MD  
Foundation for Blood Research

**A Evaluation Methods and Analytical Performance Characteristics of Immunological Assays for Human Immunoglobulin E (IgE) Antibodies of Defined Allergen Specificities; Approved Guideline (I/LA20-A) 1997**



This document provides guidance for the design, analytical performance, standardization, and quality assurance of laboratory assays used in the measurement of total serum IgE and IgE antibodies of defined allergen specificity.

**Members \$50 Nonmembers \$100**

Chairholder: Per N.J. Matsson, PhD  
Pharmacia & Upjohn



**A Clinical Evaluation of Immunoassays; Approved Guideline (I/LA21-A) 2002**

This document addresses the need for clinical evaluation of new immunoassays and new applications of existing assays. As a guide to designing and executing a clinical evaluation, this document will aid clinical and regulatory personnel responsible for commercializing products, developers of "in-house" assays for institutional use, and developers of assays used for monitoring pharmacologic effects of new drugs or biologics.

**Members \$50 Nonmembers \$100**

Chairholder: Linda Ivor  
Gen-Probe Incorporated



### **A** Assessing the Quality of Immunoassay Systems: Radioimmunoassays and Enzyme, Fluorescence, and Luminescence Immunoassays; Approved Guideline (I/LA23-A) 2004

This guideline addresses components for harmonizing and assessing the quality of immunoassay systems for several commonly used dose-response indicator categories, e.g., radioisotopes, enzymes, fluorescence, luminescence, reagents, and experimental components criteria essential to characterizing an immunoassay.

**Members \$50 Nonmembers \$100**

Chairholder: W. Harry Hannon, PhD  
Centers for Disease Control and Prevention

### **A** Fluorescence Calibration and Quantitative Measurement of Fluorescence Intensity; Approved Guideline (I/LA24-A) 2004

This guideline describes the basic principles, reference materials, and laboratory procedures upon which quantitative fluorescence calibration is based.

**Members \$50 Nonmembers \$100**

Co-Chairholders: Gerald E. Marti, MD, PhD, FDA Ctr for Biologics Evaluation/Research, and Robert F. Vogt, Jr., PhD, Centers for Disease Control and Prevention

### **A** Maternal Serum Screening; Approved Standard (I/LA25-A) 2004

This document addresses the steps required to provide reliable screening and reporting using examples of serum markers currently in common use (AFP, hCG, uE3, DIA). Outcome evaluation, information management, and calculation of risk are also emphasized in this standard.

**Members \$50 Nonmembers \$100**

Chairholder: Sanda Clejan, PhD  
Tulane University School of Medicine

### **A** Performance of Single Cell Immune Response Assays; Approved Guideline (I/LA26-A) 2004

This document contains methods of intracellular cytokine evaluation, major histocompatibility complex (MHC) tetramer quantitation, and enzyme-linked immunospot (ELISPOT) technology. This document provides basic aspects of specimen collection, transport, and preparation, in addition to quality assurance and test validation approaches. An NCCLS-IFCC joint project.

**Members \$50 Nonmembers \$100**

Chairholder: Alan L. Landay, PhD  
Rush Presbyterian-St. Luke's Medical Center

### **A** Blood Collection on Filter Paper for Newborn Screening Programs; Approved Standard - Fourth Edition (LA4-A4) 2003

This document addresses the issues associated with specimen collection, the filter paper collection device, and the transfer of blood onto filter paper, and provides uniform techniques for collecting the best possible specimen for use in newborn screening programs.

**Members \$60 Nonmembers \$120**

Chairholder: W. Harry Hannon, PhD  
Centers for Disease Control and Prevention  
See videotape section for LA4-A3-V information.

### **A** Quality Assurance for Immunocytochemistry; Approved Guideline (MM4-A) 1999

This document provides recommendations for the performance of immunocytochemical assays on cytologic and surgical pathology specimens. It is intended to promote a better understanding of the requirements, capabilities, and limitations of these diagnostic methods; to improve their intra- and inter-laboratory reproducibility; and to improve their positive and negative predictive values in the diagnosis of disease.

**Members \$60 Nonmembers \$120**

Chairholder: Timothy J. O'Leary, MD, PhD  
Armed Forces Institute of Pathology

### **A** Protocols for Evaluating Dehydrated Mueller-Hinton Agar; Approved Standard (M6-A) 1996

This standard contains procedures for evaluating production lots of Mueller-Hinton agar, and for the development and application of reference media.

**Members \$50 Nonmembers \$100**

Chairholder: George L. Evans, PhD  
Becton Dickinson Microbiology Systems



### **A** Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard - Sixth Edition (M7-A6) 2003

American National Standard. \* This newly revised standard provides updated reference methods for the determination of minimal inhibitory concentrations (MICs) for aerobic bacteria by broth macrodilution, broth microdilution, and agar dilution. **THIS DOCUMENT CONTAINS MIC INTERPRETIVE CRITERIA AND QUALITY CONTROL PARAMETERS TABLES UPDATED FOR 2004 (M100-S15).** (See related publication M11-A6 in this section.)

**Members \$150 Nonmembers \$275**

Chairholder: Mary Jane Ferraro, PhD, MPH  
Massachusetts General Hospital  
Vice-Chairholder: Matthew A. Wikler, MD, MBA  
ViroPharma, Incorporated



## MICROBIOLOGY

### **A** Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard - Eighth Edition (M2-A8) 2003

American National Standard. \* This document contains the current recommended methods for disk susceptibility testing, criteria for quality control testing, and updated tables for interpretive zone diameters. **THIS DOCUMENT IS COMPLETE WITH DISK SUSCEPTIBILITY TESTING TABLES UPDATED FOR 2004 (M100-S15).** (See related publication M7-A6.)

**Members \$150 Nonmembers \$275**

Chairholder: Mary Jane Ferraro, PhD, MPH  
Massachusetts General Hospital  
Vice-Chairholder: Matthew A. Wikler, MD, MBA  
ViroPharma, Incorporated

See videotape section for M2-A5-V information.



### M7 Quality Control Flowcharts

We are offering a laminated 8 1/2 x 11 flowchart that will provide an easy to use, easy to understand, and readily available resource of critical CLSI/NCCLS-recommended protocols for the establishment of a quality control system to be used with MIC test methods.

**Sold in sets of 5**

**Members \$35 Nonmembers \$60**

### **A** Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard - Sixth Edition (M11-A6) 2004

American National Standard. \* This standard provides reference methods for the determination of minimal inhibitory concentrations (MICs) of anaerobic bacteria by agar dilution and broth microdilution. **THIS DOCUMENT IS COMPLETE WITH TABLES FOR AST OF ANAEROBIC BACTERIA UPDATED FOR 2004.**

**Members \$85 Nonmembers \$200**

Chairholder: Matthew A. Wikler, MD, MBA  
Peninsula Pharmaceuticals, Inc.



### **A** Laboratory Diagnosis of Blood-borne Parasitic Diseases; Approved Guideline (M15-A) 2000

This document contains guidelines for specimen collection, blood film preparation, and staining procedures. Recommendations for optimum timing of specimen collection to assist laboratories in detecting, identifying, and reporting certain parasites are also included.

**Members \$60 Nonmembers \$120**

Chairholder: Lynne S. Garcia, MS, F(AAM)  
Diagnostic Medical Parasitology



### **A** Methodology for the Serum Bactericidal Test; Approved Guideline (M21-A) 1999

This guideline describes a direct method of antimicrobial susceptibility testing using a patient's serum to measure the activity of serum against bacterial pathogen isolated from the patient. (See related publication M26-A in this section.)

**Members \$60 Nonmembers \$120**

Chairholder: James H. Jorgensen, PhD  
University of Texas Health Science Branch

## MICROBIOLOGY: Susceptibility Testing

**M2-A8** Antimicrobial Disk Testing

**M7-A6** Dilution Testing (Aerobes)

\* The prices for any one of the M2-A8 or M7-A6 documents plus the M100-S15 tables are listed below:

	Members	Nonmembers
1 document & tables	\$150	\$275
2 documents & tables	\$250	\$375

### M2 Quality Control Flowcharts

We are offering a laminated 8 1/2 x 11 flowchart that will provide an easy to use, easy to understand, and readily available resource of critical CLSI/NCCLS-recommended protocols for the establishment of a quality control system to be used with disk antimicrobial susceptibility test methods.

**Sold in sets of 5**

**Members \$35 Nonmembers \$60**

**A** **Quality Control for Commercially Prepared Microbiological Culture Media; Approved Standard – Third Edition (M22-A3) 2004**

This standard contains quality assurance procedures for manufacturers and users of prepared, ready-to-use microbiological culture media.

**Members \$60 Nonmembers \$150**

Chairholder: Karen Krisher, PhD, D(ABMM)  
Oregon Public Health

**A** **Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline – Second Edition (M23-A2) 2001**

This document addresses the required and recommended data needed for the selection of appropriate interpretive standards and quality control guidelines for antimicrobial agents.

**Members \$150 Nonmembers \$250**

Chairholder: Mary Jane Ferraro, PhD, MPH  
Massachusetts General Hospital



**A** **Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard (M24-A) 2003**

This standard provides protocols and related quality control parameters and interpretive criteria for the susceptibility testing of mycobacteria, *Nocardia* spp., and other aerobic actinomycetes.

**Members \$60 Nonmembers \$120**

Chairholder: Gail L. Woods, MD  
Merck & Company, Inc.

**Quality Control MIC Limits for Mycobacterium peregrinum and Staphylococcus aureus (When Testing Rapidly Growing Mycobacteria);**



**Informational Supplement (M24-S1)**

This supplemental table provides new QC ranges for susceptibility testing for CLSI/NCCLS document M24-A – *Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard*

**Members \$15 Nonmembers \$35**

Chairholder: Gail L. Woods, MD  
Merck & Company, Inc.

**A** **Methods for Determining Bactericidal Activity of Antimicrobial Agents; Approved Guideline (M26-A) 1999**

This guideline contains procedures for determining the lethal activity of antimicrobial agents. (See related publication M21-A in this section.)

**Members \$60 Nonmembers \$120**

Chairholder: James H. Jorgensen, PhD  
University of Texas Health Science Branch

**A** **Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard – Second Edition (M27-A2) 2002**

This standard addresses the selection and preparation of antifungal agents; implementation and interpretation of test procedures; and quality control requirements for susceptibility testing of yeasts that cause invasive fungal infections.

**Members \$60 Nonmembers \$120**

Chairholder: Michael A. Pfaller, MD  
University of Iowa College of Medicine

**Quality Control MIC Limits for Broth Microdilution; Informational Supplement (M27-S1) 2004**

This supplemental table, which includes two new drugs, provides quality control limits for broth microdilution susceptibility tests of ten antifungal agents. It is available as an 8.5" X 11" laminated chart for easy posting in the laboratory.

**Members \$15 Nonmembers \$35**

**A** **Procedures for the Recovery and Identification of Parasites From the Intestinal Tract; Approved Guideline—Second Edition (M28-A2) 2005**



This guideline addresses the collection, processing, and examination of intestinal tract specimens for the identification of parasites.

**Members \$60 Nonmembers \$120**

Chairholder: Lynne S. Garcia, MS  
LSG & Associates

**A** **Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline – Third Edition (M29-A3) 2005**



Based on U.S. regulations, this document provides guidance on the risk of transmission of infectious agents by aerosols, droplets, blood, and body substances in a laboratory setting; specific precautions for preventing the laboratory transmission of microbial infection from laboratory instruments and materials; and recommendations for the management of exposure to infectious agents.

**Members \$100 Nonmembers \$200**

Chairholder: David L. Sewell, PhD  
Veterans Affairs Medical Center  
See videotape section for M29-A2 information.  
See related publication X3-R on page 27.

**A** **Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Approved Standard – Second Edition (M31-A2) 2002**

This document provides the currently recommended techniques for antimicrobial agent disk and dilution susceptibility testing, criteria for quality control testing, and interpretive criteria for veterinary use.

**Members \$60 Nonmembers \$120**

Chairholder: Thomas R. Shryock, PhD  
Elanco Animal Health

**Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals; Informational Supplement (M31-S1) 2004**

This document provides updated tables for the antimicrobial susceptibility testing standard M31-A2.

**Members \$35 Nonmembers \$60**

Chairholder: Thomas R. Shryock, PhD  
Elanco Animal Health

**P** **Evaluation of Lots of Dehydrated Mueller-Hinton Broth for Antimicrobial Susceptibility Testing; Proposed Guideline (M32-P) 2001**

This document describes methods for evaluation of production lots of Mueller-Hinton broth by manufacturers of the dehydrated product. Performance of production lots is determined by testing defined organism/antimicrobial combinations. The results of testing must conform to defined quality control limit ranges for each combination of antimicrobial and ATCC quality control strain. Guidelines

are provided for ranges of specific ion contents (cations and anions) that will provide results within the defined quality control limit ranges.

**Members \$60 Nonmembers \$120**

Chairholder: Robert P. Rennie, PhD  
University of Alberta Hospital

**A** **Antiviral Susceptibility Testing: Herpes Simplex Virus by Plaque Reduction Assay; Approved Standard (M33-A) 2004**

This document provides a protocol for the performance of the plaque reduction assay for phenotypic antiviral susceptibility testing of herpes simplex virus.

**Members \$60 Nonmembers \$120**

Co-Chairholders: Richard L. Hodinka, PhD,  
Children's Hospital of Philadelphia, and Ella M. Swierkosz,  
PhD, St. Louis University

**A** **Western Blot Assay for Antibodies to Borrelia burgdorferi; Approved Guideline (M34-A) 2000**

This document addresses technical and interpretive considerations for use of Western blot assays that detect antibodies to *Borrelia burgdorferi* and other *Borrelia* species that cause Lyme Disease.

**Members \$60 Nonmembers \$120**

Chairholder: Alan G. Barbour, MD  
University of California Irvine College of Medicine

**A** **Abbreviated Identification of Bacteria and Yeast; Approved Guideline (M35-A) 2002**

This document provides a series of microbial identification protocols that are designed to minimize the use of expensive, time-consuming laboratory tests, allowing timely reporting of accurate organism identification.

**Members \$60 Nonmembers \$120**

Chairholder: Ellen Jo Baron, PhD  
Stanford University Medical School

**A** **Clinical Use and Interpretation of Serologic Tests for Toxoplasma gondii; Approved Guideline (M36-A) 2004**

This guideline provides the user with information about the biology of *Toxoplasma gondii*, the methods available for use in the laboratory diagnosis of human toxoplasmosis, techniques that should be performed for specific clinical situations, and how to interpret laboratory results.

**Members \$60 Nonmembers \$120**

Chairholder: Lynne S. Garcia, MS, F(AAM)  
LSG and Associates

**A** **Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters for Veterinary Antimicrobial Agents; Approved Guideline – Second Edition (M37-A2) 2002**

This document addresses the required and recommended data needed for selection of appropriate interpretive standards and quality-control guidance for veterinary antimicrobial agents.

**Members \$60 Nonmembers \$120**

Chairholder: Thomas R. Shryock, PhD  
Elanco Animal Health

### **A** Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard (M38-A) 2002

This document addresses the selection of antifungal agents; preparation of antifungal stock solutions and dilutions for testing; implementation and interpretation of test procedures; and quality control requirements for susceptibility testing of filamentous fungi (moulds) that cause invasive fungal infections.

**Members \$60 Nonmembers \$120**

Chairholder: Michael A. Pfaller, MD  
University of Iowa College of Medicine

### **A** Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline (M39-A) 2002

This document describes methods for the recording and analysis of antimicrobial susceptibility test data, consisting of cumulative and ongoing summaries of susceptibility patterns of epidemiologically significant microorganisms.

**Members \$60 Nonmembers \$120**

Chairholder: Mary Jane Ferraro, PhD, MPH  
Massachusetts General Hospital

### **A** Quality Control of Microbiological Transport Systems; Approved Standard (M40-A) 2003

This standard provides criteria to manufacturers and end-users of transport devices to assist with provision of dependable products for the transport of microbiological clinical specimens. Quality control considerations are presented, as well as techniques, control organisms, and acceptability criteria. This document provides a consistent protocol for initial testing or microbiological transport devices by manufacturers and a method by which laboratories can validate manufacturer claims and compare devices. An NCCLS-DIN pilot project.

**Members \$60 Nonmembers \$120**

Co-Chairholders: Judy C. Arbiq, ART(CSMLS) CLS(NCA), Arbiq-Rendell Onsite Training and Consulting, and Barbara Ann Body, PhD, D(ABMM), LabCorp

### **P** Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated From Aquatic Animals; Proposed Guideline (M42-P) 2005

This document provides the most up-to-date techniques for disk diffusion susceptibility testing of aquatic species isolates and criteria for quality control testing.

**Members \$60 Nonmembers \$120**

Co-Chairholders: John P. Hawke, PhD, Louisiana State University, and Renate Reimschuessel, PhD, VMD, Center for Veterinary Medicine, FDA

### **A** Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline (M44-A) 2004

This guideline provides newly established methodology for disk diffusion testing of *Candida* spp., zone interpretive criteria, and recommended quality control ranges.

**Members \$85 Nonmembers \$200**

Chairholder: Daniel J. Sheehan, PhD  
Pfizer Inc

### **P** Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria; Proposed Guideline (M45-P)

**NEW**

This document provides guidance to clinical microbiology laboratories for standardized susceptibility testing of infrequently-isolated or fastidious bacteria that are not presently included in CLSI documents M2, M7, or M11. The tabular information in this document presents the most current information for drug selection, interpretation, and quality control for the infrequently-isolated or fastidious bacterial pathogens included in this guideline.

**Members \$60 Nonmembers \$120**

Chairholder: James H. Jorgensen, PhD,  
University of Texas Health Science Branch

### **P** Methods for Broth Dilution Susceptibility Testing of Bacteria Isolated From Aquatic Animals; Proposed Guideline (M49-P) 2005

**NEW**

This document provides the most up-to-date techniques for the determination of minimal inhibitory concentrations (MICs) of aquatic bacteria by broth micro- and macrodilution, and criteria for quality control testing.

**Members \$60 Nonmembers \$120**

Co-Chairholders: John P. Hawke, PhD, Louisiana State University, and Renate Reimschuessel, PhD, VMD, FDA Center for Veterinary Medicine

### Performance Standards for Antimicrobial Susceptibility Testing:

#### Fifteenth Informational Supplement (M100-S15) January 2005

This document provides updated tables for the antimicrobial susceptibility testing standards for Disk (M2-A8) and MIC (M7-A6).

**Members \$85 Nonmembers \$200**

Chairholder: Matthew A. Wikler, MD, MBA, FIDSA  
Peninsula Pharmaceuticals, Inc.

### Wallchart — Glossary of Antimicrobial Terms and Abbreviations Wallchart: Fifteenth Informational Supplement (M100-S15)

This wallchart features important terminology (drug classes, subclasses, and dosage forms) for all antimicrobial agents featured in M100. This format serves as a handy reference for laboratorians in "speaking the language" when transmitting important clinical susceptibility information to the clinician. The chart also features a comprehensive listing of abbreviations used around the world to identify antimicrobials in *in vitro* diagnostic products such as automated susceptibility test systems and antimicrobial agent disks.

**Members \$35 Nonmembers \$60**

## MOLECULAR METHODS

### **A** Molecular Diagnostic Methods for Genetic Diseases; Approved Guideline (MM1-A) 2000

This document provides guidance for the use of molecular biologic techniques for clinical detection of heritable mutations associated with genetic disease.

**Members \$60 Nonmembers \$120**

Chairholder: Dale H. Altmiller, PhD  
University of Oklahoma Health Sciences Center

**FDA**

### **A** Immunoglobulin and T-Cell Receptor Gene Rearrangement Assays; Approved Guideline – Second Edition (MM2-A2) 2002

This document provides guidance on the performance of gene rearrangement assays, including indication; specimen collection, transport, and processing; assessment of specimen adequacy; and quality control.

**Members \$60 Nonmembers \$120**

Chairholder: Russel K. Enns, PhD  
Vysis, Inc.

### **P** Molecular Diagnostic Methods for Infectious Diseases; Proposed Guideline—Second Edition (MM3-P2) 2005

This guideline addresses topics relating to clinical applications, amplified and nonamplified nucleic acid methods, selection and qualification of nucleic acid sequences, establishment and evaluation of test performance characteristics, inhibitors and interfering substances, controlling false-positive reactions, reporting and interpretation of results, quality assurance, regulatory issues, and recommendations for manufacturers and clinical laboratories.

**Members \$60 Nonmembers \$120**

Chairholder: Frederick S. Nolte, PhD  
Emory University Hospital

**FDA**

### **A** Quality Assurance for Immunocytochemistry; Approved Guideline (MM4-A) 1999

This document provides recommendations for the performance of immunocytochemical assays on cytologic and surgical pathology specimens. It is intended to promote a better understanding of the requirements, capabilities, and limitations of these diagnostic methods; to improve their intra- and inter-laboratory reproducibility; and to improve their positive and negative predictive values in the diagnosis of disease.

**Members \$60 Nonmembers \$120**

Chairholder: Timothy J. O'Leary, MD, PhD  
Armed Forces Institute of Pathology

**FDA**

### **A** Nucleic Acid Amplification Assays for Molecular Hematopathology; Approved Guideline (MM5-A) 2003

This guideline addresses the performance and application of assays for gene rearrangement and translocations by both polymerase chain reaction (PCR) and reverse transcriptase polymerase chain reaction (RT-PCR) techniques and includes information on specimen collection, sample preparation, test reporting, test validation, and quality assurance.

**Members \$60 Nonmembers \$120**

Chairholder: Timothy J. O'Leary, MD, PhD  
Armed Forces Institute of Pathology

**FDA**

**A** **Quantitative Molecular Methods for Infectious Diseases; Approved Guideline (MM6-A) 2003**

This document provides guidance for the development and use of quantitative molecular methods, such as nucleic acid probes and nucleic acid amplification techniques of the target sequences specific to particular microorganisms. It also presents recommendations for quality assurance, proficiency testing, and interpretation of results.

**Members \$60 Nonmembers \$120**

*Chairholder: Roberta M. Madej, MS, MT  
Roche Molecular Systems, Inc.*

**A** **Fluorescence In Situ Hybridization (FISH) Methods for Medical Genetics; Approved Guideline (MM7-A) 2004**

This document addresses FISH methods for medical genetic determinations, identification of chromosomal abnormalities, and gene amplification. Topics addressed include probe and assay development, qualification, and validation; instrument requirements; quality assurance; and recommendations for evaluation of results.

**Members \$60 Nonmembers \$120**

*Chairholder: Russel K. Enns, PhD  
Cepheid*

**A** **Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine; Approved Guideline (MM9-A) 2004**

This document addresses automated, PCR-based, dideoxylterminator and primer extension sequencing done on gel- or capillary-based sequencers. Topics covered include: specimen collection and handling; isolation of nucleic acid; amplification and sequencing of nucleic acids; interpretation and reporting results; and quality control/assessment considerations as appropriate.

**Members \$60 Nonmembers \$120**

*Chairholder: Michael A. Zoccoli, PhD  
Celera Diagnostics*

**P** **Genotyping for Infectious Diseases: Identification and Characterization; Proposed Guideline (MM10-P) 2005**

This guideline describes currently used analytical approaches and methodologies applied to identify the clinically important genetic characteristics responsible for disease manifestation, outcome, and response to therapy in the infectious disease setting. It also provides guidance on the criteria to be considered for design, validation, and determination of clinical utility of such testing.

**Members \$60 Nonmembers \$120**

*Chairholder: Stephen P. Day, PhD  
Third Wave Technologies, Inc.*

**P** **Diagnostic Nucleic Acid Microarrays; Proposed Guideline (MM12-P) 2005**



This guideline provides recommendations for many aspects of the array process including: a method overview; nucleic acid extraction; the preparation, handling, and assessment of genetic material; quality control; analytic validation; and interpretation and reporting of results. A CLSI-IFCC joint project.

**Members \$60 Nonmembers \$120**

*Chairholder: Joseph L. Hackett, PhD  
FDA Center for Devices and Radiological Health*

**P** **Collection, Transport, Preparation, and Storage of Specimens for Molecular Methods; Proposed Guideline (MM13-P) 2005**

This document provides guidance related to proper and safe biological specimen collection and nucleic acid isolation and purification. These topics include methods of collection, recommended storage and transport conditions, and available nucleic acid purification technologies for each specimen/nucleic acid type. A CLSI-IFCC joint project.

**Members \$60 Nonmembers \$120**

*Chairholder: Lynne Rainen, PhD  
BD Preanalytical Solutions*

**A** **Proficiency Testing (External Quality Assessment) for Molecular Methods; Approved Guideline (MM14-A) 2005**



This document provides guidelines for a quality proficiency testing program including reliable databases; design control in the choice of materials and analytes; good manufacturing processes; documentation procedures; complaint handling; corrective and preventive action plans; and responsive timing of reports. A CLSI-IFCC joint project.

**Members \$60 Nonmembers \$120**

*Chairholder: Roberta M. Madej, MS, MT  
Roche Molecular Systems, Inc.*

**P** **Use of External RNA Controls in Gene Expression Assays; Proposed Guideline (MM16-P) 2005**



This document provides protocols supporting the use of external RNA controls in microarray and QRT-PCR based gene expression experiments, including preparation of control transcripts, design of primers and amplicons, quality control, use in final experimental or clinical test application, and analysis and interpretation of data obtained. A CLSI-IFCC joint project.

**Members \$60 Nonmembers \$120**

*Chairholder: Janet A. Warrington, PhD  
Affymetrix*

## POINT-OF-CARE TESTING

**A** **Point-of-Care In Vitro Diagnostic (IVD) Testing; Approved Guideline (AST2-A) 1999**

This document contains guidelines for users of *in vitro* diagnostic (IVD) devices outside the clinical laboratory to produce reliable results comparable to those obtained in the clinical laboratory.

**Members \$60 Nonmembers \$150**

*Chairholder: Barbara M. Goldsmith, PhD  
St. Christopher's Hospital for Children*

**A** **Wellness Testing Using IVD Devices; Approved Guideline (AST3-A) 1999**

This document provides procedures and recommendations for implementing a quality wellness-testing program.

**Members \$50 Nonmembers \$100**

*Chairholder: Nina Peled, PhD  
Cygnus, Inc.*

**A** **Point-of-Care Connectivity; Approved Standard (POCT1-A) 2001**

This document provides the framework for engineers to design devices, work stations, and interfaces that allow multiple types and brands of point-of-care devices to communicate bidirectionally with access points, data managers, and laboratory information systems from a variety of vendors. An NCCLS, IFCC, CIC joint publication.

**Members \$100 Nonmembers \$150**

*Chairholder: Jeffrey A. DuBois, PhD  
Nova Biomedical Corporation*



**Note: Distributed on CD-ROM**

## Electronic Archived Documents

**These documents are no longer being reviewed as part of our consensus process. However, because of their usefulness to a limited segment of the healthcare community, we are continuing to make the documents available for their informational content. These are available in electronic format only.**

Immunoprecipitin Analyses: Procedures for Evaluating the Performance of Materials—Second Edition; Approved Guideline (DI2-A2) 1993

**Members: \$25 Nonmembers: \$75**

Agglutination Analyses: Antibody Characteristics, Methodology, Limitations, and Clinical Validation; Approved Guideline (DI3-A) 1993

**Members: \$25 Nonmembers: \$75**

Labeling of Laboratory Prepared Materials (GP4-P) 1984

**Members: \$15 Nonmembers: \$25**

Inventory Control Systems for Laboratory Supplies; Approved Guideline (GP6-A) 1994

**Members: \$50 Nonmembers: \$100**

Labeling for Home-Use *In Vitro* Testing Products; Approved Guideline (GP14-A) 1996

**Members: \$35 Nonmembers: \$85**

Histochemical Method for Leukocyte Alkaline Phosphatase; Proposed Standard (H22-P) 1984

**Members: \$25 Nonmembers: \$75**

Determination of Factor Coagulation Activities (H48-A) 1997

**Members: \$25 Nonmembers: \$75**

Temperature Calibration of Water Baths, Instruments, and Temperature Sensors—Second Edition; Approved Standard (I2-A2) 1990

**Members: \$25 Nonmembers: \$75**

Standard for Relating Spectrophotometer Performance Characteristics to Analytical Goals (I3-A) 1980

**Members: \$15 Nonmembers: \$25**

Service of Clinical Laboratory Instruments (I6-A) 1984

**Members: \$15 Nonmember: \$25**

Determining Performance of Volumetric Equipment (I8-P) 1984

**Members: \$15 Nonmembers: \$25**

Temperature Monitoring and Recording in Blood Banks (I16-T) 1986

**Members: \$15 Nonmembers: \$25**

Detection and Quantitation of Rubella IgG Antibody: Evaluation and Performance Criteria for Multiple Component Test Products, Specimen Handling, and Use of Test Products in the Clinical Laboratory; Approved Guideline (I/LA6-A) 1997

**Members: \$25 Nonmembers: \$75**

Specifications for Immunological Testing for Infectious Diseases; Approved Guideline—Second Edition (I/LA18-A2) 2001

**Members \$50 Nonmembers \$100**

Primary Reference Preparations Used to Standardize Calibration of Immunochemical Assays for Serum Prostate Specific Antigen (PSA); Approved Guideline (I/LA19-A) 1997

**Members: \$25 Nonmembers: \$75**

Assessing the Quality of Radioimmunoassay Systems; Approved Guideline - Second Edition (LA1-A2) 1994

**Members \$25 Nonmembers \$75**

Sourcebook of Reference Methods, Materials, and Related Information for the Clinical Laboratory; Proposed Guideline (NRSCL12-P) 1994

**Members: \$50 Nonmembers: \$100**

The Reference System for the Clinical Laboratory: Criteria for Development and Credentialing of Methods and Materials for Harmonization of Results; Approved Guideline (NRSCL13-A) 2000

**Members: \$50 Nonmembers: \$100**

# International Organization for Standardization (ISO) Documents

The International Organization for Standardization Technical Committee (ISO/TC) 212, *Clinical laboratory testing and in vitro diagnostic test systems*, was formed in 1995 based on a proposal by Clinical and Laboratory Standards Institute (CLSI). ISO granted the Secretariat to the American National Standards Institute (ANSI), who in turn delegated the Secretariat responsibility to us. As manager of ISO's standards-development process in this field, our role is a global one carried out on behalf of the patient-testing community throughout the world. ISO/TC 212 is not a CLSI-sponsored activity and officially, ANSI, as the U.S. member of ISO, is listed as the Secretariat of ISO/TC 212.

As a separate, distinct national responsibility, CLSI also manages the U.S. TAG for ISO/TC 212, *Clinical laboratory testing and in vitro diagnostic test systems*, and the U.S. TAG for ISO/TC 76, *Transfusion, infusion, and injection equipment for medical and pharmaceutical use*, on behalf of ANSI.

Through an agreement with ANSI, we are able to offer ISO/TC 212 and ISO/TC 76 approved and draft standards. To purchase ISO/TC 76 approved and draft standards, visit Shop at [www.clsi.org](http://www.clsi.org).

Customers from outside the United States may order these ISO standards from their national standards bodies.

## LEGEND

TR	Technical Report
DTR	Draft technical report
CD	committee draft
DIS	draft international standard

## ISO/TC 212 STANDARDS

### Medical laboratories – Particular requirements for quality and competence (ISO 15189) 2003 (formerly *Quality management in the medical laboratory*)

This International Standard specifies requirements for quality management of a medical laboratory.

**Members \$150 Nonmembers \$200**

### Medical laboratories – Requirements for safety (ISO 15190) 2003 (formerly *Safety management for medical laboratories*)

This International Standard specifies requirements for quality management of a medical laboratory.

**Members \$150 Nonmembers \$200**

### *In vitro* diagnostic medical devices – Measurement of quantities in samples of biological origin – Presentation of reference measurement procedures (ISO 15193) 2002

This International Standard specifies requirements for the drafting of a reference measurement procedure.

**Members \$100 Nonmembers \$135**

### *In vitro* diagnostic medical devices – Measurement of quantities in samples of biological origin – Description of reference materials (ISO 15194) 2002

This International Standard specifies requirements and formats for the description of reference materials.

**Members \$95 Nonmembers \$125**

### Laboratory medicine – Requirements for reference measurement laboratories (ISO 15195) 2003 (formerly *Requirements for laboratories performing reference procedures*)

This International Standard describes the specific requirements for reference measurement laboratories in laboratory medicine.

**Members \$90 Nonmembers \$120**

### *In vitro* diagnostic test systems – Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus (ISO 15197) 2003

This International Standard specifies procedures for the determination of performance criteria for quantitative *in vitro* blood glucose monitoring systems for management of diabetes mellitus.

**Members \$150 Nonmembers \$200**

### Clinical laboratory medicine – *In vitro* diagnostic medical devices – Validation of user quality control procedures by the manufacturer (ISO 15198) 2004

This International Standard specifies procedures for manufacturers of *in vitro* diagnostic devices for validating the recommendations provided in the device labeling for user quality control which assures adequate performance.

**Members \$80 Nonmembers \$110**

### *In vitro* diagnostic medical devices – Measurement of quantities in biological samples – Metrological traceability of values assigned to calibrators and control materials (ISO 17511) 2003

This International Standard specifies how to assure the metrological traceability of values assigned to calibrators and control materials intended to establish or verify trueness of measurement.

**Members \$125 Nonmembers \$165**

### Clinical laboratory testing and *in vitro* diagnostic test systems – *In vitro* monitoring systems for anticoagulant therapy self-testing (ISO/DIS 17593)

This draft International Standard specifies requirements for *in vitro* monitoring systems for vitamin-K antagonist therapy, including performance, quality assurance and user training, and procedures for the verification and the validation of performance by the intended users under actual and simulated conditions of use.

**Members \$50 Nonmembers \$100**

### Clinical laboratory testing and *in vitro* diagnostic test systems – *In vitro* diagnostic medical devices – Information supplied by the manufacturer (labelling) (ISO/CD 18113)

#### Part 1: General requirements

This International Standard will specify general requirements for information supplied by the manufacturer of *in vitro* diagnostic test systems.

**Members \$50 Nonmembers \$100**

#### Part 2: *In vitro* diagnostic reagents for professional use

This International Standard will specify requirements for information supplied by the manufacturer of *in vitro* diagnostic reagents, for professional use. This Standard will also apply to information supplied by the manufacturer with calibrators, control materials and accessories intended for use with *in vitro* diagnostic reagents for professional use.

**Members \$50 Nonmembers \$100**

### Part 3: *In vitro* diagnostic instruments for professional use

This International Standard will specify the requirements for the contents of instructions for use for *in vitro* diagnostic instruments including apparatus, equipment, calibrators and control materials for professional use.

**Members \$50 Nonmembers \$100**

### *In vitro* diagnostic medical devices – Measurement of quantities in biological samples – Metrological traceability of values for catalytic concentration of enzymes assigned to calibrators and control materials (ISO 18153) 2003

This International Standard specifies how to assure the traceability of assigned values to calibrators and control materials intended to establish or verify trueness of measurement of the catalytic concentration of enzymes. The calibrators and control materials are those provided by the manufacturers as part of, or to be used together with, *in vitro* diagnostic medical devices.

**Members \$80 Nonmembers \$110**

### *In vitro* diagnostic medical devices – Information supplied by the manufacturer with *in vitro* diagnostic reagents for staining in biology (ISO 19001) 2002

This International Standard specifies requirements for information supplied with reagents used in staining in biology.

**Members \$100 Nonmembers \$135**

### Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility devices – Part 1: Reference methods for testing the *in vitro* activity of antimicrobial agents against bacteria involved in infectious diseases (ISO/DIS 20776-1) 2005

This document, jointly developed with CEN/TC 140, describes the reference method for *in vitro* antimicrobial susceptibility testing of rapidly growing aerobic bacteria with importance in human infections.

**Members \$50 Nonmembers \$100**

### Medical laboratories – Reduction of error through risk management and continual improvement (ISO/DTR 22367)

This technical report characterizes the application of ISO 15189:2003 as a system to reduce laboratory error and improve patient safety.

**Members \$50 Nonmembers \$100**

### Medical laboratories – Guidance on laboratory implementation of ISO 15189 (ISO/TR 22869)

This Technical Report provides guidance to laboratories on how to meet the requirements contained in ISO 15189:2003 for competence and quality that are particular to medical laboratories.

**Members \$50 Nonmembers \$100**

### Point-of-care testing (POCT) – Requirements for quality and competence (ISO/DIS 22870)

This draft annex for ISO 15189 specifies quality management for point-of-care testing.

**Members \$50 Nonmembers \$100**

# Projects in Development

## NOTE:

These projects are in development; they are not available for purchase at this time.

## Automation and Informatics

### Automated Verification of Clinical Laboratory Test Results (AUTO10)

This proposed project will lead to the development of guidelines that provide requirements and recommendations for the design, building, implementation, validation, and compliance of the algorithms for automated verification of laboratory results. It will establish a means for the design of an open framework that allows users to easily configure their systems to meet the medical needs of their laboratories based on their own medical philosophies and takes into account the individual needs of their physicians as well as their patient populations.

*Chairholder: William Neeley, MD, FACP, DABCC  
Detroit Medical Center University Laboratories*

### IT Security of IVD Instruments and Software Systems (AUTO11)

This document will provide technical and operational requirements as well as technical implementation guidelines related to security of IVD systems (devices, analytical instruments, data management systems, etc.) installed at a healthcare organization.

*Chairholder: Andrzej J. Knafel, PhD  
Roche Instrument Center Ltd*

## Clinical Chemistry and Toxicology

### Analysis of Body Fluids in Clinical Chemistry (C49)

This proposed project will lead to the development of guidelines for the application of widely available analytic methods for testing body fluids and for reporting and interpreting those results. Emphasis will be placed on defining the common clinical situations for this use; acceptable practice for measuring analytes without extended method validation for abnormal body fluids; influence of biologic and analytic variation on interpretation of results; and variability in comparing results between different instrument manufacturers. A CLSI-HFCC joint project

*Chairholder: Richard A. McPherson, MD  
Virginia Commonwealth University*

### Mass Spectrometry in the Clinical Laboratory (C50)

This guideline will provide a series of guideposts, references, standards, and quality assurance markers to ensure ease of implementation and correct operation of an NMS system for the many applications in the clinical laboratory. This document will also include information regarding optimization of the analysis including maintaining optimum performance, approaches to ensuring accurate and precise mass measurement, quality control of assays and troubleshooting instrument problems versus sample preparation problems, limitations of the technology, interpretation of results, the use of relative concentrations ratios of compounds, and qualitative diagnostic profiling including protein profiling versus quantitative analysis for therapeutic monitoring.

*Chairholder: Donald H. Chace, PhD  
Pediatrix Screening*

### Expression of Uncertainty of Measurement in Clinical Laboratory Medicine (C51)

This guideline is intended for diagnostic test manufacturers, clinical laboratories, and regulatory agencies. It will describe, in clear terms understood by these three groups, the principles required for estimating measurement uncertainty as stated in the GUM. It also will discuss the limitations of the concepts of uncertainty. This document will also provide advice on how to estimate measurement uncertainty in the healthcare field in an objective, economic manner and present techniques for validating uncertainty estimates gained from simulations by experimental investigations.

*Chairholder: Richard R. Miller, Jr.  
Dade Behring Inc.*

### Validate and Implement Secondary Reference Materials (C53)

This guideline will provide recommendations on tests or procedures that should be performed to characterize secondary reference materials in a patient sample matrix.

*Chairholder: Hubert Vesper, PhD  
Centers for Disease Control and Prevention*

### Verification of Comparability of Patient Results Within One Healthcare System (C54)

This guideline will provide statistical protocols at stated power to verify the agreement between patients' results when measured on two or more instruments or methods for the same analyte.

*Chairholder: Chris Lehman, MD  
University of Utah*

## Evaluation Protocols

### Principles of Manufacturer's Validation of Risk Mitigation Using Quality Controls (EP22)

This document will describe the principles, and give procedural examples, for validation of the capability of the quality controls to mitigate the identified risks.

*Chairholder: Greg Cooper, CLS, MHA  
Bio-Rad Laboratories, Inc.*

## General Laboratory Practices

### Human Tissue Procurement (GP30)

The scope of this guideline will cover all healthcare institutions or clinics that may collect human tissue for research purposes, by providing recommendations for the collection in accordance with the practice of ethical, legislative, and legal concerns. It will also help to ensure that human tissue procurement and use for medical research can be differentiated from that involving cloning, stem cell, and organ development/replacement research. The separation is important to prevent broad actions brought against all "genetic research" involving humans from disabling diagnostic and pharmaceutical research involving human tissue and molecular genetics.

*Co-Chairholders: Sofia Gitis,  
Zion, and Kathleen M. Smith, PhD  
DNAX Research Inc.*

### Laboratory Instrument Evaluation, Verification, and Maintenance (GP31)

This guideline will provide the basic information required to make appropriate decisions concerning instrument selection, verification, and maintenance in the clinical laboratory. It will suggest reasonable and workable guidelines for laboratory personnel for fostering quality laboratory services, meeting the requirements of regulatory bodies, and using resources economically. A CLSI-CAP joint project.

*Co-Chairholders: William J. Castellani, MD,  
Penn State Hershey Medical Center, and  
Keith Kaplan, MD,  
Walter Reed Army Medical Center*

## Immunology and Ligand Assay

### Newborn Screening Follow-up (I/LA27)

Newborn screening is a system which is comprised of screening, follow-up, diagnosis, management, evaluation, and education. Follow-up is essential to assure valid screen results are known for every eligible newborn and all abnormal results are followed to definite diagnosis and appropriate clinical management is initiated and collection of long-term outcome data for program assessment and quality assurance. The primary goal of this guideline is to improve and ensure the quality of follow-up services for newborns screened through public health newborn screening programs. The quality of follow-up services directly impacts the health of newborns and families. The intent of this document is to provide a model for effective follow-up to ensure timely identification of affected infants. The discussion of newborn screening follow-up is limited to follow-up activities and will not address the analytical portion of the screening/confirmatory testing or the treatment modalities. This guideline is intended to be used globally by those who are involved in any aspect of newborn screening follow-up including: maternity and newborn healthcare providers, the medical home provider, the confirmatory services, and subspecialty medical consultants (e.g., specialists in pediatrics, hematology, endocrinology, metabolic and genetic disorders, audiology services) as well as the family.

*Chairholder: Judith Tuerck, RN, MS  
Oregon Health & Science University*

## Microbiology

### Viral Culture (M41)

This project on viral culture will provide guidance on the culturing of viruses isolated from patients. Identification techniques will also be addressed. The resulting document will cover the total patient-testing process, starting in the preanalytical phase with an outline of optimal methods for collection, preservation, and transport of clinical specimens. The viral culture document will provide details on the analytic portion of the process, featuring cell culture methodology in terms of selection and maintenance of appropriate cell lines and quality control of viral culture media. Protocols for cell culture inoculation, incubation, and quality control will be included, as well as in-depth procedures for culture reading and isolate identification and suggestions for patient reporting.

Chairholder: Lorraine M. Clarke, PhD  
New York State Department of Health

### Methods for Antimicrobial Susceptibility Testing of Human Mycoplasmas (M43)

This project will lead to a consensus guideline for methods and interpretation of *in vitro* antimicrobial susceptibilities for mycoplasmas of human origin. The protocols will be limited to methodology and interpretive criteria for *Mycoplasma pneumoniae*, *Mycoplasma hominis*, and *Ureaplasma urealyticum/parvum*.

(Although other mycoplasmas may occur in human infections, disease associations and cultivation conditions are not so well established and, therefore, these organisms are not practical to study in a project of this nature.) A CLSI-IFCC joint project.

Chairholder: Ken B. Waites, MD  
University of Alabama at Birmingham

### Diagnostic Microbiology for Limited Resources Laboratories (M46)

This document describes the performance of these tasks within the realm of the limited resources laboratory (i.e., those that have minimal means with which to perform microbiological analyses). Addressed in this document are the environment in which such diagnostic methods can be employed, minimal materials necessary for diagnostic microbiology, the education and training of personnel performing this testing, and the procedures for the production of clinically relevant patient test results within these constraints. To assist the limited resources laboratory, this document will include minimal standards of adherence necessary for good microbiology laboratory practices.

Chairholder: Susan Sharp, PhD  
Kaiser Permanente – NW

### Principles and Procedures for Blood Cultures (M47)

This guideline is intended to provide guidance to clinical microbiologists for the recovery of pathogens from blood specimens taken from patients who are suspected of having bacteremia or fungemia. Specific recommendations will be offered for the collection, transport, and processing of blood cultures.

Chairholder: Michael L. Wilson, MD  
Denver Health Medical Center

### Laboratory Diagnosis of Mycobacterial Infections (M48)

This guideline is intended to provide guidance to laboratories on the total testing process for patients with suspected mycobacterial infections. Recommendations will be offered for the collection, preservation, and transport of clinical specimens. Procedures for the direct detection of mycobacteria by microscopy and amplification techniques, the optimal recovery of mycobacteria from clinical specimens, and the identification of mycobacterial species by traditional (phenotypic) and alternative (phenotypic and genotypic) laboratory methods will be addressed.

Chairholder: Betty A. Forbes, PhD  
Medical College of Virginia

## Molecular Methods

### Molecular Methods for Bacterial Strain Typing (MM11)

This guideline will examine the biology behind molecular strain typing and the process of characterizing and validating typing systems. The guideline will describe the prevalent methods with particular attention to Pulse Field Gel Electrophoresis (PFGE) and multilocus sequence typing (MLST).

Chairholder: Robert D. Arbeit, MD  
Paratek Pharmaceuticals, Inc.

### Determining Clinical Utility of Genetic Tests (MM15)

Several government advisory committees have recently advocated that genetic testing not be performed unless "clinical utility" has been clearly demonstrated. However, this concept does not yet have a defined form in law, regulation, or guideline. The proposed project will focus on the benefits and challenges of genetic knowledge and genetic testing. The consensus guideline will provide means by which users (i.e., regulatory agencies, laboratorians, clinicians) can evaluate potential clinical utility in all phases of genetic testing. A CLSI-IFCC joint project.

Chairholder: Timothy J. O'Leary, MD, PhD  
Armed Forces Institute of Pathology

## Point-of-Care Testing

### Implementation Guide of POCT1 for Healthcare Providers (POCT2)

This guideline will provide the healthcare provider or end user with clear and concise information on what features to expect in a connectivity-compliant device. Also includes practical advice on how to apply these features to their daily operation/practice.

Co-Chairholders: Patrick St. Louis, PhD  
Sainte-Justine Hospital, and  
Louis J. Dunka, Jr., PhD  
LifeScan, Inc.

### Implementation Guide of POCT1 for Manufacturers (POCT3)

This guideline will provide a framework for IVD manufacturers to implement POCT1 into their device software.

Chairholder: Andy Quintenz  
Biosite Inc.

## Reports

### Metrological Traceability and Its Implementation (X5)

This document, being developed as a report, will provide guidance to manufacturers of IVD devices and associated materials (e.g., calibrators), on compliance with ISO 17511 and ISO 18153. It will explain traceability and where it fits in the clinical enterprise, and will include information regarding validation of comparisons, commutability, and uncertainty.

Chairholder: Marc L. Salit, PhD  
NIST

## ISO/TC 212

### ISO 18113

#### Clinical laboratory testing and *in vitro* diagnostic test systems – *In vitro* diagnostic medical devices – Information supplied by the manufacturer (labelling)

##### Part 4: *In vitro* diagnostic reagents for self-testing

This International Standard will specify requirements for information supplied by the manufacturer of *in vitro* diagnostic reagents, for self-testing. This Standard will also apply to information supplied by the manufacturer with calibrators, control materials and accessories intended for use with *in vitro* diagnostic reagents for self-testing.

##### Part 5: *In vitro* diagnostic instruments for self-testing

This International Standard specifies the requirements for the contents of instructions for use for *in vitro* diagnostic instruments including apparatus, equipment, calibrators and control materials for self-testing.

### ISO/AWI 20776

#### Susceptibility Testing

This project will be composed of two parts which are linked: 1) Standardization of reference method(s) for *in vitro* testing of the susceptibility of bacteria with importance in human infections against antimicrobial agents; and 2) Standardization in the field of bacteriology relating to the performance of antimicrobial susceptibility devices which are used for testing the susceptibility of bacteria to antibiotics in most medical laboratories. The standards will be developed as a joint activity of ISO/TC 212 and CEN/TC 140.

# Videotapes



## Quality Microcollection (H4-A3-V)

Details are given on the importance of blood collection and handling using the skin puncture method. The video also illustrates how to obtain the highest quality skin puncture specimen for laboratory testing. It is divided into six sections: safety, advantages, supplies, skin puncture procedure, handling and labeling, and a review of the skin puncture procedure. Based on the H4-A3 standard, the video package includes the video, a copy of the H4-A5 standard, and three laminated summary sheets. For more information on this document, see the entry in the Hematology section. (18 min.)

**Members \$95 Nonmembers \$175**

## Making a Difference Through Newborn Screening: Blood Collection on Filter Paper (LA4-A3-V)

This video provides a visualization of each step in the blood specimen collection process and depicts the standard of practice, as defined by our consensus process, for collecting such specimens on filter paper. It explains how to select and prepare the safest puncture site; choose the appropriate equipment; puncture the skin and apply blood to filter paper; care for the puncture site; identify and verify a valid specimen; and handle and mail the specimen to the laboratory. LA4-A4 accompanies the videotape, along with laminated summary sheets. For more information on this document, see the entry in the Immunology and Ligand Assay section. (25 min.)

**Members \$95 Nonmembers \$175**

Additional laminated sheets can be purchased separately in sets of 10.  
**Members \$25 Nonmembers \$50**

## Disk Susceptibility Testing: Step By Step (M2-A5-V)

This video illustrates preparation and standardization of a test inoculum;

inoculation of plates; and reading of zone sizes. It also explains in detail the use of tables when interpreting results and outlines the criteria for quality control testing. A special troubleshooting section is included, depicting the possible results when an inoculum is incorrectly made, when the plates are streaked improperly, or when the disks are applied inappropriately. The M2-A8 standard accompanies the videotape, along with laminated summary sheets. For more information on this document, see the entry in the Microbiology section. (23 min.)

**Members \$95 Nonmembers \$175**

**Includes M2-A8 and the M100 tables!**

## Preventing Blood-borne Pathogen Infection: Improved Practice Means Protection (M29-A2-V)

Designed to reduce the risk of acquiring an infectious disease, this educational videotape provides authoritative and practical safety recommendations. This videotape explains standard and contact precautions that should be practiced to protect the laboratorian, and provides a visualization of proper techniques to implement these precautions. Along with the M29-A3 guideline, this educational video will be useful in forming the foundation for your OSHA-required yearly blood-borne pathogen safety training. Laminated summary sheets are also included in the videotape package. For more information on this document, see the entry in the Microbiology section. (21 min.)

**Members \$115 Nonmembers \$200**

Also available in DVD. Please indicate M29-A2-DVD on order form.

## VIDEO DISCOUNTS

Discounts for multiple copies of the same title are offered. See page 36. Visit the online store at: [www.clsi.org](http://www.clsi.org)

# Infobase 2005

This user-friendly, searchable CD-ROM includes 156 approved-level CLSI/NCCLS standards and guidelines. Quickly and easily access all clinical laboratory and medical-testing best practices by locating single words or phrases used in the text.

This retrospective database contains all approved-level standards and guidelines published as of 31 December 2004.\*

### PRICES:

**Single-site\*\* Price**  
**Members \$750**  
**Nonmembers \$1500**

**LAN\*\*\* Price**  
**Members \$1750**  
**Nonmembers \$2500**

**Multiple-Site LAN\*\*\* Price - \$1500 per additional site**

**Discounts available for organizations with more than three sites. Call CLSI at +610.688.0100 for more information.**

### Shipping/Handling (flat rates)

Shipping and Handling for within North America \$7.50  
 Shipping and Handling for outside North America \$25.00

### BENEFITS

**Easy:** Adobe Acrobat Reader is on the CD-ROM for easy installation.

**Faster:** Queries provide quick references at your fingertips.

**Productive:** Less time spent searching through paper documents.

**Flexible:** Format allows information to be viewed online or to be printed using Adobe Acrobat Reader.

\* Internet access required for search capabilities.

\*\* Single site is for one workstation or stand-alone computer.

\*\*\* LAN refers to local area network for multiple users at one site.

## The NCCLS Procedure Manual Toolkit (GP2-A4-C) Improving procedure writing in the clinical laboratory

The major concepts of document control are presented in a user-friendly format that is easy to read and implement, thanks to the Toolkit CD. The CD includes the following nine templates with illustrative examples that provide the framework for developing procedures and communicating and organizing information:

- Analytical quantitative procedures;
- Analytical qualitative procedures (e.g., dipstick, slide, immunohematology tests);
- Pre- and post-nonanalytical procedures;
- Analyzer procedures;
- Laboratory information system procedures;
- Master document index (an Excel template is also included to facilitate sorting of data);
- Document change request form for approving new documents or changing previously approved documents;
- Comparison of analytic-specific attributes by analyzer type; and
- Analytic attributes for analyzers.

These templates enable one to establish a starting point for creating one's own laboratory-specific procedure manual. The templates allow the user to enter information into a "boiler plate" file where the parameters are preformatted – headers and footers are set. The user can simply open the template and fill in the blanks. A few samples are provided so that the user has a visual representation of the various sections of the completed procedure.

The *Toolkit* includes a copy of the revised, approved-level document GP2-A4—*Clinical Laboratory Technical Procedure Manuals; Approved Guideline—Fourth Edition* in PDF format and the *Toolkit* User Manual.

This essential *Toolkit* is applicable to any size laboratory, and will be a valuable resource for creating quality procedures.

### System Requirements

- Microsoft Windows 98/NT/2000/XP
- Microsoft Word for Windows 2000/2002/2003

**Members: \$120      Nonmembers: \$235**

# Training and Competence Assessment Toolkit (GP21-A2-C)

AVAILABLE  
OCTOBER 2005

The *GP21 Training and Competence Assessment Toolkit* is based on CLSI/NCCLS document, GP21-A2, *Training and Competence Assessment; Approved Guideline—Second Edition*, which provides useful information for the development of training and competence assessment programs to verify that staff demonstrate the knowledge and skills necessary for their assigned work processes and procedures.

This toolkit is a powerful device for implementing GP21-A2. It lays the foundation for:

- ensuring that training has taken place and is documented, and
- assessing the competence of personnel in their assigned job tasks, initially and periodically thereafter.

The templates contained herein can be applied when training new employees, introducing new processes or methods, assessing initial competence, and performing periodic reassessments of competence.

The *GP21 Training and Competence Assessment Toolkit* includes the following Microsoft Word templates:

For training:

- Training Guide Form
- Trainer Responsibilities Form
- Learner Responsibilities Form
- Evaluation of Training Experience Form
- Training Checklist Form

For competence assessment:

- Written Assessment Form
- Direct Observation Checklist Form
- Competence Assessment Form—Quantitative Parallel Testing
- Competence Assessment Form—Qualitative Parallel Testing
- Follow-up of Competence or Learning Assessment Requiring Remediation Form

## System Requirements

- Microsoft Windows 98/NT/2000/XP
- Microsoft Word for Windows 97/2000/2002
- Adobe Acrobat Reader 4 or above is required for viewing the User Manual and the GP21-A2 document. The newest version is available from <http://www.adobe.com>. Adobe Acrobat Reader 6.0 is located in the *GP21 Training and Competence Assessment Toolkit* program directory (usually c:\program files\gp21).

## User Requirements

- Basic understanding of Windows user interface and file system
- Basic to intermediate understanding of Microsoft Word

**Members \$120**

**Nonmembers \$235**

## The NCCLS Quality System Toolkit (HS1-A-C)

The **NCCLS Quality System Toolkit** is based on *A Quality System Model for Health Care; Approved Guideline* (HS1-A), which provides useful information for designing, implementing, and maintaining an effective quality system.

The **Toolkit** is a powerful device for implementing HS1-A. It lays the foundation for:

- developing quality policies based on Quality System Essentials;
- outlining quality processes;
- controlling documents; and
- reporting and tracking occurrences.

In addition to the guideline and a *User Manual*, the **Toolkit** includes templates for developing, in a consistent format, documentation that supports your quality system.

The **Toolkit** includes the following Microsoft Word templates:

### **Policy or process creation:**

- Quality Policy Template
- Quality Process Template
- Flowchart Template

### **Document management:**

- Master Document Index\*
- Document Change Request Form

### **Occurrence management:**

- Occurrence Report Form Template
- Occurrence Tracking Form Template

\*In addition, Excel documents for the Master Document Index and Occurrence Tracking Form are included to facilitate sorting of data.

## **System Requirements**

- Microsoft Windows 98/NT/2000/XP
- Microsoft Word for Windows 2000/2002/2003
- Microsoft Excel (for two templates that are duplicated in Word)

**Members: \$120      Nonmembers: \$235**

# Own the Complete Library of CLSI/NCCLS Standards and Guidelines

## The CLSI Library

**Members \$2,750**

**Nonmembers \$4,000**

plus shipping and handling as follows:

North America – \$75

Outside North America – \$250

## Boxes

(set of five)

**Members \$20**

**Nonmembers \$20**

plus shipping and handling as follows:

North America – \$7.50

Outside North America – \$10.00

## Three-Ring Binder

**Members \$20**

**Nonmembers \$20**

plus shipping and handling as follows:

North America – \$7.50

Outside North America – \$10.00



*The complete, up-to-date library of more than 150 standards and guidelines encompassing patient-testing areas is available to help healthcare professionals achieve quality performance and safety.*

**Automation documents (AUTO 1-5) are included.**



*Library boxes are available to help organize and preserve your standards and guidelines. Made of high-quality, durable polypropylene, the file cases make it easy to organize and display your library attractively.*



*Use this three-ring binder to create your own collection of standards and guidelines unique to your practice.*

**NOW  
AVAILABLE**

## The CLSI Library on CD-ROM

The complete, up-to-date library on CD-ROM

Members: \$2,750 Nonmembers: \$4,000

**with no charge for shipping.**

## CLSI Publications

Our publications focus on medical-testing procedures, bench and reference methods, quality control, and scientific evaluation protocols. They provide reliable and realistic working standards and guidelines that healthcare professionals can use in daily activities and in solving practical problems.

Consensus is achieved through broad input from the medical-testing community. We encourage thorough review of all standards and guidelines, particularly at the proposed level.

**Proposed:** A proposed standard or guideline undergoes the first stage of review within the consensus process. It should receive wide and thorough review, including an overall review of its scope and approach, and a line-by-line review of technical and editorial content. This review is intended to ensure the utility and readability of approved standards and guidelines, reflecting a broad consensus.

**Approved:** An approved standard or guideline should be reviewed to assess utility of the final document and attainment of consensus (i.e., that comments on earlier versions have been satisfactorily addressed), and to identify the need for additional standards.

The **Electronic Subscription Service** is available to member organizations! Organizations that subscribe to the service can view and/or download an unlimited number of standards and guidelines. Access to this password-protected site is available to any employee of a participating member organization. The subscription service starts at \$1,500,\* with the additional fee based on the number of users.

\* The subscription service now includes all the laboratory automation standards.



Nonmember organizations can now purchase the Electronic Subscription Service starting at \$5,000.

For more information, call CLSI at +610.688.0100 or e-mail us at [customerservice@clsi.org](mailto:customerservice@clsi.org).

## Total Error Estimator (EP21-A-C)

This software add-in is based on EP21-A, *Estimation of Total Analytical Error for Clinical Laboratory Methods; Approved Guideline*, which provides users with a means to estimate total analytical error for an assay. Total Error Estimator is a powerful tool for implementing the protocols for judgment of the clinical acceptability of new methods using patient specimens and/or monitoring an assay's total analytical error by using quality control samples, as described in EP21-A.

System Requirements: Microsoft® Office 97 or later

**Members \$250      Nonmembers \$350**

## Performance Standards for Antimicrobial Susceptibility Testing (M100 CD-ROM)

This CD-ROM includes all the M100-S15 tables for the Disk Diffusion (M2) and Aerobic Dilution (M7) susceptibility testing documents. The corresponding methodology documents, M2-A8 and M7-A6, are also included on the CD-ROM.

**Members \$250      Nonmembers \$375**

For the latest news and updates, subscribe to CLSI eNews. You can join by (1) going to our main website at <http://www.clsi.org>, (2) going to the "News & Events" section, (3) clicking "Subscribe to CLSI eNews."

## Implementing a Needlestick and Sharps Injury Prevention Program in the Clinical Laboratory; A Report (X3-R)

This report presents a step-by-step approach for implementing safer medical devices that reduce or eliminate sharps injuries to laboratory personnel. X3-R is written in an expanded checklist format, outlines a process that goes beyond general recommendations, and specifically addresses the needs of professionals performing specimen collection and clinical laboratory procedures. It outlines the important steps laboratory professionals must take to:

- identify devices that have the potential for causing injury;
- select safer medical devices for evaluation;
- evaluate selected devices;
- adopt the new devices for routine use; and
- implement a continuous quality improvement process.

**Members: \$65      Nonmembers \$150**

The "Needlestick Report" is an essential reference source for implementing requirements of the *Revised OSHA Bloodborne Pathogen Standard*, as well as analyzing and improving practices, with the goal of providing a safer work environment.

### Working Group on Needlestick Prevention

Geraldine L. Barnes, M.T.(ASCP), M.S., *Clinical and Laboratory Standards Institute*  
 M. Clare Edelmayer, M.T.(ASCP), R.N., M.S., *Doylestown Hospital*  
 Beverly Kovanda, Ph.D., *Columbus State Community College*  
 Donna M. Meyer, Ph.D., *CHRISTUS Health*  
 David Sewell, Ph.D., *Veterans Affairs Medical Center*



## Planning for Challenges to Clinical Laboratory Operations During a Disaster; A Report (X4-R)

This document provides guidance on steps to be taken by the clinical laboratory to be prepared in the event of an emergency. X4-R is written for use by laboratory managers, directors, and supervisors, and is intended to provide a checklist of considerations to be used to assess preparedness and begin planning for continuance and redirection of clinical laboratory services during emergency situations.

**Members: \$65      Nonmembers \$150**

### Working Group on Emergency Response

J. Rex Astles, Ph.D., *FACB, Centers for Disease Control and Prevention*  
 Thomas L. Hearn, Ph. D., *Centers for Disease Control and Prevention*  
 Lawrence B. Kaplan, Ph.D., *FACB, Bellevue Hospital Center*  
 Anthony R. Sambol, MA, *SM(NRM), SV(ASCP), CBSP, Nebraska Health and Human Services System*  
 Thomas L. Williams, M.D., *FACB, FASCP, FCAP, Methodist Hospital*



## Proceedings From the QC for the Future Workshop; A Report (X6-R)

CLSI, in conjunction with its organizing partners, convened the *QC for the Future* workshop in Baltimore, MD, on 18 March. The purpose of this workshop was to provide attendees with the opportunity to learn about current and new technologies for quality control, to discuss potential approaches for future quality control, and to develop new ideas for implementing quality control for the future. CLSI and the workshop co-sponsors anticipate that these proceedings will serve as a focal point for continued discussion and informed action on this important topic.

**Members: \$15      Nonmembers \$25**

### QC for the Future Workshop Sponsoring Organizations:

American Association for Clinical Chemistry	Centers for Medicare & Medicaid Services
American Clinical Laboratory Association	College of American Pathologists
American Medical Technologists	CLMA
American Society for Clinical Laboratory Science	Clinical and Laboratory Standards Institute (CLSI)
American Society for Clinical Pathology	COLA
American Society for Microbiology	Joint Commission on Accreditation of Healthcare Organizations
Advanced Medical Technology Association (AdvaMed)	U.S. Food and Drug Administration
Centers for Disease Control and Prevention	

# Product Price Listing

## VIDEOTAPES

**H4-A3-V**, Quality Microcollection  
Members \$95 Nonmembers \$175

**LA4-A3-V**, Newborn Screening  
Members \$95 Nonmembers \$175

**M2-A5-V**, Disk Susceptibility Testing  
Members \$95 Nonmembers \$175

**M29-A2-V or DVD**, Preventing  
Blood-borne Pathogen Infection  
Members \$115 Nonmembers \$200

## ELECTRONIC PRODUCTS

**ISO/TC 76 Library of Standards**  
\$2500

**Library - CD ROM**  
Members \$2750 Nonmembers \$4000

**Electronic Subscription Service**  
Including Automation Standards  
Members\* \$1500 Nonmembers\* \$5000

**Infobase 2005**  
Members \$750 Nonmembers \$1500  
Single-Site LAN Price:  
Members \$1750 Nonmembers \$2500  
Multiple-Site LAN Price: \$1500 per site

**EP21-A-C**, Total Error Estimator  
Members \$250 Nonmembers \$350

**GP2-A4-C**, The NCCLS Procedure  
Manual Toolkit  
Members \$120 Nonmembers \$235

**GP21-A2-C**, Training and Competence  
Assessment  
Members \$120 Nonmembers \$235

**HS1-A-C**, The NCCLS Quality System  
Toolkit  
Members \$120 Nonmembers \$235

**M100-CD ROM**  
Members \$250 Nonmembers \$375

## SPECIALTY COLLECTIONS

**SC1-L**, Evaluation Protocols  
Members \$340 Nonmembers \$645

**SC2-L**, Specimen Collection  
Members \$280 Nonmembers \$570

**SC7-L**, General Hematology  
Members \$190 Nonmembers \$400

**SC10-L**, Laboratory Safety  
Members \$175 Nonmembers \$400

**SC11-L**, CLIA Collection  
Members \$150 Nonmembers \$300

**SC12-L**, Coagulation  
Members \$85 Nonmembers \$185

**SC14-L**, LIS  
Members \$250 Nonmembers \$500

**SC15-L**, Technical Laboratory  
Management  
Members \$185 Nonmembers \$410

**SC16-L**, Admin. Laboratory Management  
Members \$200 Nonmembers \$460

**SC17-L**, Point-of-Care Testing  
Members \$265 Nonmembers \$545

**SC18-L**, Body Fluid  
Members \$150 Nonmembers \$280

**SC20-L**, Blood Collection Centers  
Members \$240 Nonmembers \$480

**SC21-L**, Susceptibility Testing  
Members \$465 Nonmembers \$880

**SC22-L**, General Microbiology  
Members \$375 Nonmembers \$725

**SC23-L**, Flow Cytometry  
Members \$160 Nonmembers \$330

**SC24-L**, Quality Series  
Members \$370 Nonmembers \$730

**SC25-L**, Molecular Methods  
Members \$270 Nonmembers \$570

**SC26-L**, Veterinary Microbiology  
Members \$230 Nonmembers \$450

**SC27-L**, Laboratory Automation  
Members \$350 Nonmembers \$650

**SC28-L**, Patient Assessment and Requisition  
Members \$150 Nonmembers \$320

**SC30-L**, Quality Basics  
Members \$190 Nonmembers \$350

**SC31-L**, Regulatory Compliance  
Members \$375 Nonmembers \$850

## STANDARDS & GUIDELINES

### Automation and Informatics

**AUTO1-A**, Specimen Container/  
Specimen Carrier  
Members \$50 Nonmembers \$100

**AUTO2-A**, Bar Codes for Specimen  
Container Identification  
Members \$50 Nonmembers \$100

**AUTO3-A**, Communications with  
Automated Clinical Laboratory Systems  
Members \$50 Nonmembers \$100

**AUTO4-A**, Systems Operational  
Requirements  
Members \$50 Nonmembers \$100

**AUTO5-A**, Electromechanical Interfaces  
Members \$50 Nonmembers \$100

**AUTO7-A**, Specimen Identification  
Members \$150 Nonmembers \$250

**AUTO8-P**, LIS Validation  
Members \$50 Nonmembers \$100

**AUTO9-P**, Remote Access  
Members \$50 Nonmembers \$100

**GP19-A2**, Laboratory Instruments and  
Data Management Systems  
Members \$60 Nonmembers \$120

**LIS1-A**, Specification for Low-Level  
Protocol to Transfer Messages Between  
Clinical Laboratory Instruments and  
Computer Systems  
Members \$65 Nonmembers \$120

**LIS2-A2**, Specification for Transferring  
Information Between Clinical Instruments  
and Computer Systems  
Members \$65 Nonmembers \$120

**LIS3-A**, Guide for Selection of a Clinical  
Laboratory Information Management System  
Members \$60 Nonmembers \$120

**LIS4-A**, Guide for Documentation of  
Clinical Laboratory Computer Systems  
Members \$60 Nonmembers \$120

**LIS5-A**, Specifications for Transferring  
Clinical Observations Between Indepen-  
dent Computer Systems  
Members \$60 Nonmembers \$120

**LIS6-A**, Practice for Reporting Reliability  
of Clinical Laboratory Information Systems  
Members \$60 Nonmembers \$120

**LIS7-A**, Specification for Use of Bar  
Codes on Specimen Tubes in the Clinical  
Laboratory  
Members \$60 Nonmembers \$120

**LIS8-A**, Guide for Functional Require-  
ments of Clinical Laboratory Information  
Management Systems  
Members \$60 Nonmembers \$120

**LIS9-A**, Guide for Coordination of  
Clinical Laboratory Services within the  
Electronic Health Record Environment and  
Networked Architectures  
Members \$60 Nonmembers \$120

### Clinical Chemistry and Toxicology

**AST4-A2**, Blood Glucose Testing  
Members \$60 Nonmembers \$120

**C3-P4**, Reagent Water  
Members \$60 Nonmembers \$120

**C24-A2**, Statistical Quality Control for  
Quantitative Measurements  
Members \$60 Nonmembers \$120

**C28-A2**, Reference Intervals  
Members \$60 Nonmembers \$120

**C29-A2**, Sodium and Potassium  
Ion-Selective Electrode Systems  
Members \$60 Nonmembers \$120

**C30-A2**, Bedside Blood Glucose Testing  
Members \$60 Nonmembers \$120

**C31-A2**, Ionized Calcium Determinations  
Members \$60 Nonmembers \$120

**C34-A2**, Sweat Testing  
Members \$60 Nonmembers \$120

**C37-A**, Commutable Frozen Human Serum  
Members \$60 Nonmembers \$120

**C38-A**, Trace Element Determinations  
Members \$60 Nonmembers \$120

**C39-A**, Ionized Calcium in Serum  
Members \$60 Nonmembers \$120

**C40-A**, Analytical Procedures for the  
Determination of Lead in Blood and Urine  
Members \$60 Nonmembers \$120

**C42-A**, Erythrocyte Protoporphyrin Testing  
Members \$50 Nonmembers \$100

**C43-A**, Gas Chromatography/Mass  
Spectrometry (GC/MS)  
Members \$60 Nonmembers \$120

**C44-A**, Harmonization of Glycoglo-  
bin Measurements  
Members \$60 Nonmembers \$120

**C45-A**, Measurement of Free Thyroid  
Hormones  
Members \$60 Nonmembers \$120

**C46-A**, Blood Gas and pH Analysis  
Members \$60 Nonmembers \$120

**C48-A**, Application of Biochemical  
Markers  
Members \$60 Nonmembers \$120

**H11-A4**, Collection of Arterial Blood  
Specimens  
Members \$60 Nonmembers \$120

**H17-A**, Serum Iron, Total Iron-Binding  
Capacity and Percent Transferrin Saturation  
Members \$60 Nonmembers \$120

**T/DM6-A**, Blood Alcohol Testing  
Members \$50 Nonmembers \$100

**T/DM8-A**, Urine Drug Testing  
Members \$50 Nonmembers \$100

### Evaluation Protocols

**EP5-A2**, Precision Performance of  
Clinical Chemistry Devices  
Members \$85 Nonmembers \$200

**EP6-A**, Quantitative Measurement  
Procedures  
Members \$60 Nonmembers \$120

**EP7-A**, Interference Testing  
Members \$85 Nonmembers \$200

**EP9-A2**, Method Comparison and Bias  
Estimation Using Patient Samples  
Members \$60 Nonmembers \$120

**EP10-A2**, Quantitative Clinical Lab. Methods  
Members \$60 Nonmembers \$120

**EP12-A**, Qualitative Test Performance  
Members \$60 Nonmembers \$120

**EP13-R**, Standard Deviation Report  
Members \$60 Nonmembers \$120

**EP14-A2**, Evaluation of Matrix Effects  
Members \$60 Nonmembers \$120

**EP15-A2**, Verification for Precision and Trueness  
Members \$60 Nonmembers \$120

**EP17-A**, Limits of Detection  
Members \$60 Nonmembers \$120

**EP18-A**, Quality Management for Unit-Use Testing  
Members \$60 Nonmembers \$120

**EP19-R**, A Framework for NCCLS Evaluation Protocols  
Members \$60 Nonmembers \$120

**EP21-A**, Total Error  
Members \$60 Nonmembers \$120

**General Laboratory Practices**

**GP2-A4**, Technical Procedure Manuals  
Members \$85 Nonmembers \$200

**GP5-A2**, Clinical Laboratory Waste Management  
Members \$60 Nonmembers \$120

**GP9-A**, Selecting and Evaluating a Referral Laboratory  
Members \$50 Nonmembers \$100

**GP10-A**, Lab. Tests Using ROC Plots  
Members \$50 Nonmembers \$100

**GP11-A**, Cost Accounting  
Members \$60 Nonmembers \$120

**GP15-A2**, Papanicolaou Technique  
Members \$60 Nonmembers \$120

**GP16-A2**, Collection, Transportation, and Preservation of Urine Specimens  
Members \$60 Nonmembers \$120

**GP17-A2**, Clinical Laboratory Safety  
Members \$60 Nonmembers \$120

**GP18-A**, Laboratory Design  
Members \$50 Nonmembers \$100

**GP20-A2**, FNAB Techniques  
Members \$50 Nonmembers \$100

**GP21-A2**, Training and Competence Assessment  
Members \$50 Nonmembers \$100

**GP22-A2**, Continuous Quality Improvement  
Members \$85 Nonmembers \$200

**GP23-A**, Nongynecologic Cytologic Specimens  
Members \$60 Nonmembers \$120

**GP26-A3**, Application of a Quality Management System Model for Laboratory Services  
Members \$85 Nonmembers \$200

**GP27-A**, Using Proficiency Testing (PT) to Improve the Clinical Laboratory  
Members \$50 Nonmembers \$100

**GP28-A**, Microwave Device Use  
Members \$60 Nonmembers \$120

**GP29-A**, Validation of Tests  
Members \$60 Nonmembers \$120

**Healthcare Services**

**HS1-A2**, Quality Management System Model  
Members \$85 Nonmembers \$200

**HS2-A**, Provider-Performed Microscopy Testing  
Members \$50 Nonmembers \$100

**HS3-A**, Pulse Oximetry  
Members \$50 Nonmembers \$100

**HS4-A**, A Quality System Model for Respiratory Services  
Members \$50 Nonmembers \$100

**HS5-A**, A Quality System Model for Imaging Services  
Members \$50 Nonmembers \$100

**HS6-A**, Studies to Evaluate Patient Outcomes  
Members \$50 Nonmembers \$100

**HS10-A**, A Quality System for Inpatient Medication Use  
Members \$50 Nonmembers \$100

**HS11-P**, Medical Device Hazards and Recalls  
Members \$50 Nonmembers \$100

**Hematology**

**H1-A5**, Tubes and Additives for Venous Blood Specimen Collection  
Members \$50 Nonmembers \$100

**H2-A4**, Reference and Selected Procedure for the Erythrocyte Sedimentation Rate (ESR) Test  
Members \$50 Nonmembers \$100

**H3-A5**, Collection of Diagnostic Blood Specimens by Venipuncture  
Members \$85 Nonmembers \$200

**H4-A5**, Collection of Capillary Blood Specimens  
Members \$60 Nonmembers \$120

**H7-A3**, Determining Packed Cell Volume by the Microhematocrit Method  
Members \$60 Nonmembers \$120

**H15-A3**, Reference and Selected Procedures for the Quantitative Determination of Hemoglobin in Blood  
Members \$50 Nonmembers \$100

**H18-A3**, Handling and Processing of Blood Specimens  
Members \$60 Nonmembers \$120

**H20-A**, Reference Leukocyte Differential Count (Proportional) and Evaluation of Instrumental Methods  
Members \$50 Nonmembers \$100

**H21-A4**, Blood Specimens for Coagulation Testing  
Members \$85 Nonmembers \$200

**H26-A**, Internal Quality Control of Multichannel Hematology Analyzers  
Members \$50 Nonmembers \$100

**H30-A2**, Plasma Fibrinogen Determination  
Members \$60 Nonmembers \$120

**H38-P**, Automated Hematology Analyzers  
Members \$50 Nonmembers \$100

**H42-A**, Flow Cytometry: Quality Assurance and Immunophenotyping of Lymphocytes  
Members \$50 Nonmembers \$100

**H43-A**, Flow Cytometry: Immunophenotyping of Leukemic Cells  
Members \$50 Nonmembers \$100

**H44-A2**, Reticulocyte Counting  
Members \$50 Nonmembers \$100

**H45-A2**, Bleeding Time Test  
Members \$50 Nonmembers \$100

**H47-A**, One-Stage Prothrombin Time Test and Activated Partial Thromboplastin Time Test  
Members \$50 Nonmembers \$100

**H49-A**, Point-of-Care Monitoring of Anticoagulation Therapy  
Members \$50 Nonmembers \$100

**H51-A**, Assays of von Willebrand Factor Antigen  
Members \$60 Nonmembers \$120

**H52-A**, Fetal Red Cell Detection  
Members \$60 Nonmembers \$120

**H54-A**, PT/INR Systems  
Members \$50 Nonmembers \$100

**H56-P**, Cellular Composition  
Members \$50 Nonmembers \$100

**Immunology and Ligand Assay**

**I/LA2-A**, Indirect Immunofluorescence Test for Autoantibodies to Nuclear Antigen  
Members \$50 Nonmembers \$100

**I/LA15-A**, Apolipoprotein Immunoassays  
Members \$50 Nonmembers \$100

**I/LA20-A**, Immunological Assays for Human Immunoglobulin E (IgE) Antibodies  
Members \$50 Nonmembers \$100

**I/LA21-A**, Clinical Evaluation of Immunoassays  
Members \$50 Nonmembers \$100

**I/LA23-A**, Assessing the Quality of Immunoassay Systems  
Members \$50 Nonmembers \$100

**I/LA24-A**, Fluorescence Calibrator and Quantitative Measurement  
Members \$50 Nonmembers \$100

**I/LA25-A**, Maternal Serum Screening  
Members \$50 Nonmembers \$100

**I/LA26-A**, Performance of Single Cell Immune Response Assays  
Members \$50 Nonmembers \$100

**LA4-A4**, Blood Collection on Filter Paper for Newborn Screening Programs  
Members \$60 Nonmembers \$120

**MM4-A**, Quality Assurance for Immunocytochemistry  
Members \$60 Nonmembers \$120

**Microbiology**

**M2-A8**, Antimicrobial Disk Susceptibility  
Members \$150 Nonmembers \$275

**M6-A**, Dehydrated Mueller-Hinton Agar  
Members \$50 Nonmembers \$100

**M7-A6**, Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically  
Members \$150 Nonmembers \$275

**M11-A6**, Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria  
Members \$85 Nonmembers \$200

**M15-A**, Laboratory Diagnosis of Blood-borne Parasitic Diseases  
Members \$60 Nonmembers \$120

**M21-A**, Serum Bactericidal Test  
Members \$60 Nonmembers \$120

**M22-A3**, Microbiological Culture Media  
Members \$60 Nonmembers \$150

**M23-A2**, Development of *In Vitro* Susceptibility Testing Criteria and Quality Control Parameters  
Members \$150 Nonmembers \$250

**M24-A**, Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes  
Members \$60 Nonmembers \$120

**M24-S1**, Supplemental Table  
Members \$15 Nonmembers \$35

**M26-A**, Bactericidal Activity of Antimicrobial Agents  
Members \$60 Nonmembers \$120

**M27-A2**, Broth Dilution Antifungal Susceptibility Testing of Yeasts  
Members \$60 Nonmembers \$120

**M27-S1**, Quality Control MIC Limits for Broth Microdilution  
Members \$15 Nonmembers \$35

**M28-A2**, Recovery and Identification of Parasites  
Members \$60 Nonmembers \$120

**M29-A3**, Protection of Laboratory Workers from Occupationally Acquired Infections  
Members \$100 Nonmembers \$200

**M31-A2**, Antimicrobial Disk/Dilution Susceptibility Tests for Bacteria Isolated from Animals  
Members \$60 Nonmembers \$120

**M31-S1**, Supplemental Table  
Members \$35 Nonmembers \$60

**M32-P**, Evaluation of Lots of Mueller Hinton Broth for AST  
Members \$60 Nonmembers \$120

**M33-A**, Antiviral Susceptibility Testing  
Members \$60 Nonmembers \$120

**M34-A**, Western Blot Assay for Antibodies  
Members \$60 Nonmembers \$120

**M35-A**, Abbreviated Identification of Bacteria and Yeast  
Members \$60 Nonmembers \$120

**M36-A**, Clinical Use and Interpretation of Serologic Tests for *Toxoplasma gondii*  
Members \$60 Nonmembers \$120

**M37-A2**, *In Vitro* for Veterinary Antimicrobial Agents  
Members \$60 Nonmembers \$120

**M38-A**, Reference Method for Broth Dilution  
Members \$60 Nonmembers \$120

**M39-A**, Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data  
Members \$60 Nonmembers \$120

**M40-A**, QC of Microbiological Transport  
Members \$60 Nonmembers \$120

**M42-P**, Methods for Antimicrobial Disk Susceptibility Testing of Bacteria Isolated from Aquatic Animals  
Members \$60 Nonmembers \$120

**M44-A**, Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts  
Members \$85 Nonmembers \$200

**M45-P**, Fastidious Bacteria  
Members \$60 Nonmembers \$120

**M49-P**, Dilution AST Aquatic Animals  
Members \$60 Nonmembers \$120

**M100-S15**, Supplemental Tables  
Members \$85 Nonmembers \$200

**Molecular Methods**

**MM1-A**, Molecular Diagnostic Methods for Genetic Diseases  
Members \$60 Nonmembers \$120

**MM2-A2**, Immunoglobulin and T-Cell Receptor Gene Rearrangement Assays  
Members \$60 Nonmembers \$120

**MM3-P2**, Molecular Diagnostic Methods  
Members \$60 Nonmembers \$120

**MM5-A**, Nucleic Acid Amplification Assays for Molecular Hematopathology  
Members \$60 Nonmembers \$120

**MM6-A**, Quantitative Molecular Diagnostics  
Members \$60 Nonmembers \$120

**MM7-A**, FISH Methods  
Members \$60 Nonmembers \$120

**MM9-A**, Nucleic Acid Sequencing  
Members \$60 Nonmembers \$120

**MM10-P**, Genotyping for Infectious Disease  
Members \$60 Nonmembers \$120

**MM12-P**, Nuclear Acid Microarrays  
Members \$60 Nonmembers \$120

**MM13-P**, Collection and Handling of Specimens for Molecular Methods  
Members \$60 Nonmembers \$120

**MM14-A**, Proficiency Testing  
Members \$60 Nonmembers \$120

**MM16-P**, External RNA Controls  
Members \$60 Nonmembers \$120

**Point-of-Care Testing**

**AST2-A**, Point-of-Care IVD Testing  
Members \$60 Nonmembers \$150

**AST3-A**, Wellness Testing Using IVD Devices  
Members \$50 Nonmembers \$100

**POCT1-A**, Point-of-Care Connectivity  
Members \$100 Nonmembers \$150

**Library**

Members \$2700 Nonmembers \$4000

Boxes (set of three)  
Members \$20 Nonmembers \$20

Three-Ring Binder  
Members \$20 Nonmembers \$20

**Reports**

X3-R Needlestick Prevention Program  
Members \$65 Nonmembers \$150

X4-R Challenges to Clinical Laboratory Operations During Disasters  
Members \$65 Nonmembers \$150

X6-R Proceedings from the QC for the Future Workshop  
Members \$15 Nonmembers \$25

## The Quality Management System Approach

*Facilitate licensure, satisfy accreditation, build credibility, reduce operating costs, and achieve success*

CLSI subscribes to a quality management system approach in the development of standards and guidelines. This approach facilitates project management; defines document structure via a template; and provides a process to identify needed documents through a gap analysis.

*A Quality Management System Model for Health Care (HS1)* provides a structure for a comprehensive, systematic approach to build quality into a healthcare service's processes, assess the service's performance, and implement quality improvements.

The document includes 12 "quality system essentials" or "QSEs." Information is provided about the processes and procedures that a healthcare organization or service needs to have in place to ensure that its work operations are functioning as intended to meet customer, regulatory, and accreditation requirements, and to provide for the highest level of patient safety.

Learn more about the **CLSI Quality Management System Approach**, visit [www.clsi.org](http://www.clsi.org)

# Subject Index

## Documents, Products, and Projects

Topic	Order Code	Page	Topic	Order Code	Page	Topic	Order Code	Page
<b>A</b>								
Abbreviated bacterial identification	M35-A	14	Aquatic	M42-P	15	Blood gas		
Accuracy	EP15-A2	9	Arterial blood	M49-P	15	Blood collection	H11-A4	9
Activated partial thromboplastin time (APTT)	H21-A4	11	Assessment of sensitivity	H11-A4	9		SC2-L	3
	H47-A	12		SC2-L	3	Blood glucose testing	C46-A	8
	SC12-L	3	Automation	GP10-A	10		AST4-A2	8
Additives				SC1-L	3		ISO 15197	18
EDTA	H1-A5	11		AUTO1-A	6	Blood lead	C40-A	8
Heparin	H1-A5	11		AUTO2-A	6	Body fluids	GP23-A	10
Tubes	H1-A5	11		AUTO3-A	6		H56-P	12
Aerosols	M29-A3	14		AUTO4-A	6	Bone markers	C48-A	9
Airborne transmission	M29-A3	14		AUTO5-A	7	Breakpoint development	M23-A2	14
Alcohol	T/DM6-A	9		AUTO8-P	7	Bronchoalveolar lavage	H56-P	12
Allergy techniques	I/LA20-A	12		AUTO9-P	7	Broth microdilution	M38-A	15
Allowable difference	EP6-A	9					M49-P	15
Allowable error	EP6-A	9	<b>B</b>					
Alpha-fetoprotein	I/LA25-A	13	Bacterial identification	M35-A	14	Calcium, ionized	C31-A2	8
Ambulatory blood glucose	AST4-A2	8	Bactericidal activity	M21-A	13		C39-A	8
Amplification	MM1-A	15		M26-A	14	Calibration	C24-A2	8
	MM3-P2	15	Bar Code	SC21-L	4		H26-A	11
	MM5-A	15		AUTO2-A	6		H54-A	12
	MM6-A	16	Bias	AUTO7-A	7	Calibration and control materials	ISO 17511	18
	MM9-A	16	Device	EP15-A2	9		ISO 18153	18
	MM12-P	16	Evaluation	EP9-A2	9		H56-P	12
Anaerobic reference	M11-A6	13		SC1-L	3	Cerebrospinal fluid	H56-P	12
	SC21-L	4		EP10-A2	9	Certified plasmas	H54-A	12
Analytical instruments	AUTO3-A	6		SC1-L	3	Chloride, sweat	C34-A2	8
Analytical run	C24-A2	8		SC11-L	3	Chromosome	MM7-A	16
Ancillary blood glucose	C30-A2	8		EP14-A2	9	Citrate	H21-A4	11
Animal	M37-A2	14		H45-A2	12	CLIA regulations	SC11-L	3
Antifungal reference method	M27-A2	14	Matrix effect	M29-A3	14	Clinical evaluation	I/LA21-A	12
	M38-A	15	Bleeding time	M29-A3	14	Clinical laboratory automation	AUTO3-A	6
	M44-A	15	Biological safety cabinet	T/DM6-A	9	Clinical laboratory water	C3-P4	8
Antimicrobial agents	M2-A8	13	Blood-borne pathogens			Clinical trials	I/LA21-A	12
	M37-A2	14	Blood alcohol			Clinical utility	*MM15	20
	M42-P	15	Blood collection			Coagulation	H21-A4	11
	M2-A8	13	Arterial	H11-A4	9	APTT	H47-A	12
	M7-A6	13	Children	H4-A5	11	Calibration Plasma	H54-A	12
	M11-A6	13		H4-A3-V	21	Factors	H21-A4	11
	SC21-L	4	Coagulation	H21-A4	11	Factor VIII	SC12-L	3
	SC22-L	4		H54-A	12		MM5-A	15
	*M43	20	Filter paper	SC2-L	3	Fibrinogen	H30-A2	11
	M32-P	14	Neonatal	SC12-L	3		SC12-L	3
	M31-A2	14	Skin puncture	LA4-A4	13	Point-of-Care	H49-A	12
	M42-P	15		LA4-A4	13	PT	H47-A	12
	M49-P	15	Specialty collection	LA4-A3-V	21	Ristocetin cofactor	H51-A	12
Antimicrobial susceptibility	M2-A8	13	Tubes	H4-A5	11	Specialty collection	SC12-L	3
	M7-A6	13	Venipuncture	H4-A3-V	21	Specimen collection	H21-A4	11
	M11-A6	13	Blood count	H4-A3-V	21	von Willebrand factor	H51-A	12
	SC21-L	4	Differential	SC2-L	3	Collection		
	SC22-L	4	PCV	H1-A5	11	Blood	H3-A5	11
	*M43	20		H3-A5	11		LA4-A4	13
Veterinary	M32-P	14		H20-A	11		SC2-L	3
	M31-A2	14		H7-A3	11			
	M42-P	15		SC7-L	3			
	M49-P	15						
Antimycobacteria	M24-A	14						
	M24-S1	14						
Antinuclear antibodies (ANA)	I/LA2-A	12						
Antiviral susceptibility testing	M33-A	14						
Apolipoproteins	I/LA15-A	12						
Aquaculture	M49-P	15						





Topic	Order Code	Page	Topic	Order Code	Page	Topic	Order Code	Page
pH	C46-A	8						
Phlebotomy			Quality control	MM14-A	16	<b>S</b>		
Additives	H1-A5	11		C24-A2	8	Safety	AST3-A	16
Arterial	H11-A4	9		EP5-A2	9	Hazardous waste	GP5-A2	10
	SC2-L	3		GP9-A	10	Laboratory safety	ISO 15190	18
Handling	H18-A3	11		H26-A	11		SC10-L	3
	SC7-L	3		H42-A	12	Needlestick prevention	X3-R	27
			Failures	M40-A	15	Protection from infectious disease		
Skin puncture	H4-A5	11	Hematology instrumentation	*M41	20		M29-A3	14
	H4-A3-V	21		GP22-A2	10		M29-A2-V	21
	SC2-L	3		H20-A	11	Sample storage	H21-A4	11
Tubes	H1-A5	11		H26-A	11	Schlichter test	M21-A	13
Phlebotomy (continued)			Leukemia phenotyping	SC7-L	3	SED rate	SC21-L	4
Venipuncture	H3-A5	11	Media	H43-A	12		H2-A4	11
	SC2-L	3	Principles/definitions	M22-A3	14		SC7-L	3
Platelet	H45-A2	12		C24-A2	8	Selection	GP9-A	10
Pleural fluid	H56-P	12	Rules	SC15-L	4	Semiquantitative testing	EP12-A	9
PO <sub>2</sub>	C46-A	8	Quality improvement	SC11-L	3	Sensitivity	GP10-A	10
Point-of-care (POC) testing			Quality management	C24-A2	8		SC1-L	3
Administrative guidelines	AST2-A	16		GP22-A2	10	Sequencing	MM9-A	16
Connectivity	POCT1-A	16	Quality management system	ISO 15189	18		MM10-P	16
Coagulation testing	H49-A	12		GP26-A3	10	Serous fluid	H56-P	12
Potentiometry	C39-A	8		HS1-A2	6	Serum		
Precision	EP5-A2	9		HS4-A	6	Alpha fetoprotein	I/LA25-A	13
	EP15-A2	9	Quantitation	HS5-A	6	Serum Cholesterol	C37-A	8
	SC1-L	3		HS10-A	6	Skin puncture	H4-A5	11
Preliminary evaluation	EP10-A2	9		EP17-A	9		H4-A3-V	21
Procedure manuals	GP2-A4	10	<b>R</b>				SC2-L	3
	GP2-A4-C	22	Radioactive waste			SNP	MM10-P	16
	SC11-L	3	Radioimmunoassay (RIA)	GP5-A2	10	Standardization	C29-A2	8
	SC15-L	4	Reagent water	I/LA23-A	13	Sweat	C34-A2	8
Process instruments	AUTO3-A	6		C3-P4	8	Software	GP19-A2	7
Proficiency testing	GP27-A	11	Reference intervals	SC15-L	4	User interfaces	GP19-A2	7
	GP29-A	11	Reference materials	SC28-A2	8	End-user validation	GP19-A2	7
	MM14-A	16		I/LA15-A	12	Southern blot	MM1-A	15
Protection				ISO 15194	18		MM2-A2	15
Infectious disease	M29-A3	14		M6-A	13		MM5-A	15
	M29-A2-V	21	Reference measurement				MM12-P	16
	SC2-L	3	laboratories	ISO 15195	18	Specialty collections		
	SC10-L	3	Repeatability	EP15-A2	9	Administrative laboratory management	SC16-L	4
Instrument biohazards	SC10-L	3	Reference measurement procedures	ISO 15193	18	ASTM collection	SC14-L	3
	M29-A3	14	Reference methods	H2-A4	11	Blood collection centers	SC20-L	4
Protein				H20-A	11	Body fluids and tissue specimen collection	SC18-L	4
Apolipoprotein	I/LA15-A	12		SC7-L	3	CLIA collection	SC11-L	3
Prothrombin time (PT)	H21-A4	11		I/LA15-A	12	Coagulation	SC12-L	3
	H47-A	12		M11-A6	13	Evaluation protocols	SC1-L	3
	H54-A	12		M27-A2	14	Flow cytometry	SC23-L	5
	SC12-L	3		SC21-L	4	General hematology	SC7-L	3
Protoporphyrin testing	C42-A	8		SC22-L	4	General microbiology	SC22-L	4
Pulse oximetry	HS3-A	6	Referral laboratories	SC16-L	4	Laboratory automation	SC27-L	5
Purified water	C3-P4	8	Primary	GP9-A	10	Laboratory safety	SC10-L	3
			Repeatability	EP15-A2	9	Molecular methods	SC25-L	5
			Respiratory care	HS4-A	6	Patient assessment	SC28-L	5
			Reticulocyte counting	H44-A2	12	Point-of-care testing	SC17-L	4
				SC7-L	3	Regulatory compliance	SC31-L	5
<b>Q</b>				MM16-P	16	Quality basics	SC30-L	5
QRT-PCR	MM16-P	16	RNA controls	AUTO1-A	6	Quality series	SC24-L	5
Qualitative testing	EP12-A	9	Robotics (laboratory)	AUTO3-A	6	Veterinary microbiology	SC26-L	5
Quality assessment	MM14-A	16		AUTO5-A	7	Specimen collection	SC2-L	3
Quality assurance	AST4-A2	8				Susceptibility testing	SC21-L	4
	GP22-A2	10						
	M22-A3	14						

Topic	Order Code	Page	Topic	Order Code	Page
Technical laboratory management	SC15-L	4	<i>Toxoplasma gondii</i>	M36-A	14
Specimen			Trace element analysis	C38-A	8
Collection (Coag)	H21-A4	11	Traceability	ISO 17511	18
(Molecular)	MM13-P	16		ISO 18153	18
Container/carrier	AUTO1-A	6	Training and competence assessment	GP21-A2	10
Fecal	M28-A2	14		SC16-L	4
Handling	H18-A3	11	Transferrin	H17-A	9
	SC7-L	3	Transportation	SC15-L	4
	SC15-L	4	Trueness	EP15-A2	9
Identification	AUTO2-A	6			
	AUTO7-A	7	<b>U</b>		
Processing	C46-A	8	Uncertainty	EP6-A	9
Transport	H18-A3	11	Universal precautions	AST3-A	16
	H21-A4	11		M29-A3	14
	MM13-P	16	Urinalysis	GP16-A2	10
	SC15-L	4		SC2-L	3
SRM 956a	C39-A	8	Urine collection	SC2-L	3
Staining in biology	ISO 19001	18	Drug testing	T/DM8-A	9
Standard dilution methods	M37-A2	14			
Standard disk diffusion test	M37-A2	14	<b>V</b>		
Standard precautions	M29-A3	14	Validation	AUTO8-P	7
Statistics	EP13-R	9		ISO 15198	18
	EP19-R	10	Venipuncture	H3-A5	11
Susceptibility testing	M37-A2	14		SC2-L	3
	M38-A	15	Verification	EP15-A2	9
Aquatic	M42-P	15		H54-A	12
Anaerobic	M11-A6	13	Veterinary		
Antimycobacterial	M24-A	14	Antimicrobial susceptibility testing	M31-A2	14
	M24-S1	14		M31-S1	14
Antiviral	M33-A	14		M42-P	15
Dilution tests	M7-A6	13	Antimicrobial agents	M49-P	15
Disk	M2-A8	13		M37-A2	14
	M2-A5-V	21		M42-P	15
Fungal	M27-A2	14	Videotapes		21
MIC	M7-A6	13	Viral	*M41	20
Quality control	M23-A2	14			
	M32-P	14	<b>W</b>		
Specialty collection	SC21-L	4	Waste	GP5-A2	10
Veterinary	M31-A2	14		SC10-L	3
Sweat testing	C34-A2	8	Water purification	C3-P4	8
Symbol	AUTO2-A	6	Wellness testing	AST3-A	16
Synovial fluid	H56-P	12			
System status/performance	AUTO4-A	6	<b>Y</b>		
			Yeast susceptibility	M27-A2	14
<b>T</b>					
Template	H45-A2	12			
Thrombin time	H21-A4	11			
Thromboplastin	H54-A	12			
TIBC	H17-A	9			
T-cell receptor gene rearrangements	MM2-A2	15			
Tissue differentiation antigens	MM4-A	15			
Tonometry	C46-A	8			
Total error	EP6-A	9			
Total iron binding capacity	H17-A	9			
Toxicology					
Blood alcohol testing	T/DM6-A	9			
Drug monitoring	T/DM8-A	9			

# How to Order

## NOTE:

### MULTIPLE-COPY DISCOUNTS

Discounts for multiple copies of the same title are offered as follows:

# COPIES	PRICE PER COPY
1 - 5	Full price
6 - 10	5% discount
11 - 20	15% discount
21 - 99	25% discount
100 - 499	35% discount
500 - 999	45% discount

If your country is on the World Bank or Global AIDS Program list, or if you are conducting training in these areas, contact CLSI for pricing.

### ORDER BY MAIL

Complete the form on page 37 and mail with payment or purchase order to:

**Clinical and Laboratory Standards Institute**  
**940 West Valley Road, Suite 1400**  
**Wayne, PA 19087-1898 USA**

### ORDER BY PHONE: +610.688.1100 OR TOLL-FREE +877.447.1888

Save time by calling us to place your order. Please have your credit card number handy. **We do not accept purchase orders over the phone or electronically. Purchase orders must be faxed or mailed.**

### ORDER BY FAX: +610.688.0700

When you order by FAX, please do **not** send an additional hard copy by mail.

### ORDER VIA OUR WEBSITE: WWW.CLSI.ORG

Use this site for ordering standards, guidelines, videotapes, and applications with VISA, MasterCard, American Express, or Discover.

### ORDER VIA WIRE TRANSFER:

Commerce Bank, Valley Forge Office  
 100 East Swedesford Road, Devon, PA 19333 USA  
 Bank Routing Number (ABA) 031201360  
 Account number 360967061

### SHIPPING/HANDLING

**Within North America:** add 10% (min. \$7.50). **Outside North America:** International Surface (allow one week for delivery), add 35% (min. \$10); International Express (1-3 day delivery), add 45% (min. \$10).

### FOREIGN CURRENCY

Please contact CLSI for an exchange rate quotation.  
 All prices are quoted in U.S. currency.

Express Shipping*	2-Day	Standard	Priority
1-3 documents	\$11	\$16	\$23
4-6 documents	\$14	\$19	\$26
7-10 documents	\$16	\$21	\$28
Specialty Collections	\$15	\$20	\$28
Library	\$40	\$75	\$100

\*The express charge is in addition to the regular shipping and handling charges.

# Order Form

See order instructions and pricing information on previous page

## Bill to: (Please Print)

Name: \_\_\_\_\_  
 Organization: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City: \_\_\_\_\_ State/Province: \_\_\_\_\_  
 Zip/Postal Code: \_\_\_\_\_ Country: \_\_\_\_\_  
 Telephone: \_\_\_\_\_ FAX: \_\_\_\_\_  
 E-mail: \_\_\_\_\_

I would not like to receive printed versions of any promotions.

## Ship to If different than Bill to (Please Print):

Name: \_\_\_\_\_  
 Organization: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City: \_\_\_\_\_ State/Province: \_\_\_\_\_  
 Zip/Postal Code: \_\_\_\_\_ Country: \_\_\_\_\_  
 Telephone: \_\_\_\_\_ FAX: \_\_\_\_\_  
 E-mail: \_\_\_\_\_

Organizational website: \_\_\_\_\_

Qty.	Order Code	Title	Price		Total
			Member	Nonmbr.	

Prices subject to change.

## Membership Status:

Member Organization  
 Nonmember Organization  
 Membership Identification #: \_\_\_\_\_

## Method of payment (Check one):

Payment enclosed in full.  
 VISA       MasterCard       AMEX       Discover

Card Number: \_\_\_\_\_

Signature: \_\_\_\_\_

Exp. Date (Mo./Yr.): \_\_\_\_\_

Send me an invoice. Purchase order MUST be faxed or mailed.  
 Full payment is due upon receipt of invoice.

Federal Tax ID #23-7089361

## Orders Outside North America

Orders outside North America require a purchase order, a check drawn on a U.S. bank, or credit card.

## NOTE:

Due to the overwhelming volume of faxes we receive, we are unable to respond to confirmation requests. If you need to know pricing, you may call CLSI before faxing your purchase order.

Subtotal  
 Shipping/handling (See previous page)  
 Express shipping  
 Foreign currency (Amount quoted)  
 Sales tax (PA shipments add 6%)  
 Total



## MAIL TO:

Clinical and Laboratory Standards Institute  
 940 West Valley Road, Suite 1400  
 Wayne, PA 19087-1898 USA

ORDER BY PHONE: +610.688.1100

ORDER BY FAX: +610.688.0700

WEBSITE: [www.clsi.org](http://www.clsi.org)

To place an order using our toll-free order line, dial 877.447.1888. To call toll-free from outside the U.S. and Canada, first dial your country's Direct Access Number, available on the AT&T website at [www.att.com](http://www.att.com).

Thank you for your order!

Please photocopy this form for multiple orders.

# Membership Information

**Membership in CLSI is the most effective way to participate in the voluntary consensus process. We offer a wide range of membership categories designed to meet every organization's goals, activities, needs, and resources. All membership categories are open on a worldwide basis. Listed below are the membership categories.**

**Active Members** include professional, clinical, and trade associations; government agencies; medical-testing consultants; and large and small companies in the medical-testing and *in vitro* diagnostic products fields. These organizations participate through representation on committees and voting on technical and administrative issues in the development and evaluation of standards and guidelines. Government, professional societies, and trade organizations can have two representatives, a delegate and an alternate delegate.

**Associate Active Members** are those Corresponding Member institutions interested in a broader level of participation in the voluntary consensus process. This membership allows institutions to receive all proposed standards and guidelines and to vote on all candidate-for-advancement standards and guidelines.

- **Healthcare Delivery Systems** is well suited for hospital/healthcare systems with multiple-site laboratories. In this category, a system's central facility receives, in printed and in electronic format, all newly published approved standards and guidelines with the privilege of duplicating/disseminating information in printed format for the multiple-site laboratories/facilities.
- **Comprehensive** is for institutions interested in receiving documents in both printed and electronic formats.
- **Core** is well suited for institutions performing a broad spectrum of medical testing in all disciplines covered by our standards and guidelines at a single site.

**Corresponding Members** include teaching institutions, hospitals, clinics, and independent laboratories. These members receive approved-level documents. We offer a wide range of Corresponding Membership categories from which an organization can choose based on its level of involvement in medical testing and specific interests and needs. There are four levels of Corresponding Membership from which to choose:

- **Comprehensive** is for institutions interested in receiving documents in both printed and electronic formats.
- **Core** is well suited for institutions performing a broad spectrum of medical testing in all disciplines covered by our standards and guidelines at a single site.
- **Customized** is tailored for small institutions or departments performing specialized, discipline-specific, or a limited number or variety of medical tests.  
**NEW** — Choice of receiving documents in electronic or printed format.
- **Basic** is our basic membership category. This level is designed specifically for organizations interested in, and who want to stay informed of, CLSI activities, and who may only need to purchase an occasional standard, guideline, or other product.

**Education Members** are formally organized education programs concerned with the primary education of professionals involved with medical testing. The membership provides an important communication network allowing educators to seek solutions to educational issues from other professionals in the field.

## Special Thanks to Sustaining Members

### GOLD LEVEL

Ortho-Clinical Diagnostics, Inc.  
National Institute of Standards and Technology (NIST)

### SILVER LEVEL

Abbott Laboratories  
American Association for Clinical Chemistry  
AstraZeneca Pharmaceuticals  
Bayer Corporation  
BD  
Beckman Coulter, Inc.  
bioMérieux Inc.  
CLMA  
College of American Pathologists  
GlaxoSmithKline  
Pfizer Inc  
Roche Diagnostics, Inc.

# Membership Application

Date: \_\_\_\_\_

## Please Indicate Level of Membership

(See previous page for description)

### ACTIVE MEMBERS

Please indicate organization type, and details on annual dues and benefits will be forwarded to you (check one):

- Industry** (any manufacturer or supplier to the patient testing and *in vitro* diagnostic fields)  
Annual dues are based on gross sales of products and proportional sales in allied fields.
- \$2,000 (Gross sales to \$500,000)     \$11,750 (To \$100 million)  
 \$3,500 (To \$2 million)     \$13,500 (To \$250 million)  
 \$4,750 (To \$5 million)     \$15,500 (To \$500 million)  
 \$6,500 (To \$10 million)     \$17,500 (To \$750 million)  
 \$8,250 (To \$25 million)     \$19,500 (To \$1 billion)  
 \$10,000 (To \$50 million)     \$21,500 (Over \$1 billion)  
*Start-up Company dues are \$1,000 per year.*
- Trade Assn.**     **Gov't. Agency**     **Prof. Society**  
*Selected Interest dues \$1,300 per year.  
 Broad Interest dues are \$3,300 per year.*
- Consulting Firm**  
*Annual dues are \$700 for firms with 1-2 employees and \$1,000 for firms with more than 3 employees.*

### ASSOCIATE ACTIVE MEMBERS

- Healthcare Delivery Systems**
- \_\_\_\_\_ Comprehensive \$1,800    \$ \_\_\_\_\_  
 \_\_\_\_\_ Basic Service Site(s)\*@\$275 each    \$ \_\_\_\_\_  
 (\$50 discount does not apply)
- Comprehensive** \$1,500\*\*  
 **Core** \$1,100

\*In order to be eligible for Healthcare Delivery Systems membership, contact names and addresses for each site MUST be included.

\*\*Includes the Infobase on CD-ROM; contact CLSI for LAN prices

### CORRESPONDING MEMBERS

- Comprehensive** \$1,300\*\*     **Core** \$900  
 **Customized** \$600\*\*\*     **Basic** \$300  
 (\$50 discount does not apply)

\*\*Includes the Infobase on CD-ROM; contact CLSI for LAN prices

\*\*\*Coupons do not apply for ISO documents

### EDUCATION MEMBERS

- Formalized Education Program    \$300

### SUBSCRIPTIONS

- Emeritus    FREE

### TOTAL MEMBERSHIP FEE

Less \$50.00 discount\*    \$ \_\_\_\_\_

\$ \_\_\_\_\_

### TOTAL ENCLOSED\*

\$ \_\_\_\_\_

\*Subtract \$50 discount from your membership fee if you choose to receive membership documents in electronic format only. Benefits apply to documents published during your membership year.

Contact Name: \_\_\_\_\_

Title: \_\_\_\_\_

Department: \_\_\_\_\_

Organization: \_\_\_\_\_

Street Address: \_\_\_\_\_

City: \_\_\_\_\_ State/Province: \_\_\_\_\_

Zip/Postal Code: \_\_\_\_\_ Country: \_\_\_\_\_

Telephone: \_\_\_\_\_

FAX: \_\_\_\_\_

E-mail: \_\_\_\_\_

Organizational website: \_\_\_\_\_

- I would not like to receive printed versions of any promotions.

### Method of Payment

- Payment enclosed in full.

- VISA     MasterCard     AMEX     Discover

Card No. \_\_\_\_\_

Exp. Date (Mo./Yr.) \_\_\_\_\_

Name on Card \_\_\_\_\_

- Purchase Order MUST be faxed or mailed.

Full payment is due upon receipt of invoice.

Mail to: **Clinical and Laboratory Standards Institute**  
**940 West Valley Road, Suite 1400**  
**Wayne, PA 19087-1898 USA**

You may **fax** the application if using a credit card or a purchase order. FAX: +610.688.6400

To place an order using our toll-free order line, dial 877.447.1888. To call toll-free from outside the U.S. and Canada, first dial your country's Direct Access Number, available on the AT&T website at [www.att.com](http://www.att.com).

**Save \$50**  
**on membership fees!**  
**Choose electronic distribution**  
**of documents.**

If you have questions or require additional information, please call CLSI at +610.688.0100.

## COME VISIT US...

### **45th Annual ICAAC**

21-24 September 2005  
New Orleans, Louisiana, USA  
CLSI Booth #1254

### **109th USAHA / 44th AAVLD Annual Meeting**

5-7 November 2005  
Hershey, Pennsylvania, USA  
CLSI Booth #22

### **Annual HIMSS Conference and Exhibition**

12-16 February 2006  
San Diego, California, USA  
CLSI Booth #7328

### **CLMA ThinkLab '06**

18-21 March 2006  
Charlotte, North Carolina, USA

### **2006 Clinical and Laboratory Standards Institute Leadership Conference**

26-28 April 2006  
Sheraton Premiere at Tysons Corner  
Vienna, Virginia, USA

For more  
information, check out  
our website  
**[www.clsi.org](http://www.clsi.org)**  
or contact CLSI at  
**+610.688.0100**



Nonprofit Org.  
U.S. Postage  
**PAID**  
Permit No. 50  
Downingtown, PA

940 West Valley Road, Suite 1400  
Wayne, PA 19087-1898 USA  
Phone: +610.688.0100  
Fax: +610.688.0700  
E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org)  
Website: [www.clsi.org](http://www.clsi.org)

**If you receive a duplicate  
copy of this catalog, please  
pass it on to a coworker.**